US20110196340A1 - Loading and release of water-insoluble drugs - Google Patents
Loading and release of water-insoluble drugs Download PDFInfo
- Publication number
- US20110196340A1 US20110196340A1 US13/085,623 US201113085623A US2011196340A1 US 20110196340 A1 US20110196340 A1 US 20110196340A1 US 201113085623 A US201113085623 A US 201113085623A US 2011196340 A1 US2011196340 A1 US 2011196340A1
- Authority
- US
- United States
- Prior art keywords
- balloon
- paclitaxel
- blood vessel
- drug
- wall
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/085—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M29/00—Dilators with or without means for introducing media, e.g. remedies
- A61M29/02—Dilators made of swellable material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
- A61L2300/222—Steroids, e.g. corticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1075—Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1081—Balloon catheters with special features or adapted for special applications having sheaths or the like for covering the balloon but not forming a permanent part of the balloon, e.g. retractable, dissolvable or tearable sheaths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1088—Balloon catheters with special features or adapted for special applications having special surface characteristics depending on material properties or added substances, e.g. for reducing friction
Definitions
- the invention relates to methods and devices for the localized delivery of substantially water-insoluble drug agents within the body.
- systemic administration of drug agents treats the body as a whole even though the disease to be treated may be localized.
- systemic administration may not be desirable because, for example, the drug agents may have unwanted effects on parts of the body which are not to be treated, or because treatment of the diseased part of the body requires a high concentration of drug agent that may not be achievable by systemic administration.
- U.S. Pat. No. 5,304,121 discloses a method of delivering water-soluble drugs to tissue at desired locations of a body lumen wall. The method generally includes the steps of impregnating a hydrogel polymer on an expandable catheter with an aqueous drug solution, inserting the catheter into a blood vessel to a desired location, and expanding the catheter against the surrounding tissue allowing the release of the drug to the tissue.
- This method of localized drug delivery using hydrogel polymer impregnation has a limitation of being applicable to drug agents which are dissolved in water at concentrations sufficient for therapeutic gel loading levels.
- a method and apparatus for the localized delivery of drug agents within the body where the drug agents are substantially water-insoluble.
- a method and implantable device that provides a sustained release of such substantially water-insoluble drug agents over a time frame effective to inhibit proliferative disease.
- One objective of the present invention is to provide a method and apparatus for the localized delivery of substantially water-insoluble drug agents to predetermined locations within the human body.
- a further objective of the present invention is to provide a method and apparatus to facilitate gradual, localized release of drug agents at predetermined locations within the human body.
- a further objective of the invention is to administer drug agents by diffusion directly into the tissue requiring treatment.
- the drug is preferably applied in a manner that does not further injure the tissue to be treated, and administration is selectively and evenly distributed over the treated area such that the drug can be taken up by the tissue, without, for example, being washed away by body fluids.
- the present invention provides methods and medical devices for the localized delivery of substantially water-insoluble drugs agents.
- a particular embodiment of the present invention features a catheter and method for delivering substantially water-insoluble drug agents to tissue at a desired location along body lumen walls.
- the catheter is constructed for insertion in a body lumen and has a catheter shaft and an expandable portion mounted on the catheter shaft.
- the expandable portion is expandable to fill the cross-section of the body lumen.
- At least a portion of the exterior surface of the expandable portion is defined by a polymer coating.
- Incorporated into the polymer coating is at least one substantially water-insoluble drug.
- the catheter is positioned to a desired target location within the body, whereupon the polymer coating absorbs water, thus dissolving the drug and resulting in the diffusion of the drug out of the polymer coating.
- the polymer and drug are selected to allow controlled release of a desired dosage of the drug from the polymer.
- Another particular embodiment of the present invention features a stent for the localized delivery of substantially water-insoluble drug agents to tissue at a desired location along body lumen walls.
- the stent is at least partially coated with a polymer coating having at least one substantially water-insoluble drug therein.
- the stent configuration, polymer and drug are selected to allow for the controlled release dosage and release rate of the drug from the polymer.
- the stent is a patterned stent for the localized delivery of paclitaxel to tissue at a desired location along body lumen walls.
- the stent is at least partially coated with a polymer/paclitaxel matrix that provides sustained release of paclitaxel at the desired site within the lumen wall.
- a method for preventing or inhibiting proliferative disease in a patient comprising implanting a patterned stent comprising an outer coating of polymer/paclitaxel at a site of cellular proliferation, wherein the paclitaxel is released from the outer coating at a release rate and for a period of time sufficient to inhibit or prevent cellular proliferation at the site.
- FIG. 1 a shows one embodiment of the present invention in which a drug solution is impregnated into a polymer-coated balloon catheter.
- FIG. 1 b shows the insertion of a polymer-coated balloon catheter into a body lumen, in accordance with the present invention.
- FIG. 1 c shows the expansion of a polymer-coated balloon catheter at an occlusion site within a body lumen, in accordance with the present invention.
- FIG. 2 shows a drug delivery balloon catheter embodiment of the present invention including a sheath for covering the catheter as it is being moved through a vessel toward the occlusion to be treated.
- FIGS. 3 a and 3 b show the release profile of paclitaxel from a balloon catheter having a polyacrylic acid-based coating for up to 50 and 5000 minutes, respectively, in accordance with the present invention.
- FIGS. 4 a and 4 b show the release profile of dexamethasone from a balloon catheter having a polyacrylic acid-based coating for up to 30 and 400 minutes, respectively, in accordance with the present invention.
- FIG. 5 shows the release profiles of molsidomine from various balloon catheters having a polyacrylic acid-based coating for up to 5 minutes, in accordance with the present invention.
- FIG. 6 shows the release profiles of dexamethasone from various balloon catheters having a polyacrylic acid-based coating for up to 450 minutes, in accordance with the present invention.
- FIGS. 7 a and 7 b show the release profiles of water-soluble and substantially water-insoluble estradiol from balloon catheters having a polyacrylic acid-based coatings for up to 10 and 200 minutes, respectively, in accordance with the present invention.
- FIG. 8 shows the release profile of paclitaxel for up to 10 days from polyurethane coated stents dipped in 30 mg/ml paclitaxel in ethanol for 3 days, in accordance with the present invention.
- FIG. 9 shows the release profiles of paclitaxel from various polyurethane-coated balloon catheters for up to 2 hours, in accordance with the present invention.
- FIG. 10 shows the cumulative release profile of paclitaxel over a time frame of days. This figure shows the cumulative release of paclitaxel for delivery rates of 5 ⁇ g/day and 0.5 ⁇ g/day.
- the present invention provides methods and medical devices for the localized delivery of one or more substantially water-insoluble drug agents to predetermined locations within the human body, such as within the vascular system, urinary tract, prostate, esophagus, colon, brain, etc.
- a substantially water-insoluble drug agent is dissolved in a volatile organic solvent.
- Organic solvent is intended to mean a singular organic solvent or a solvent mixture having at least one organic component.
- the solvent mixture also includes mixtures of water with miscible organic solvents.
- the drug solution is then applied to a polymer coating on a medical device that is adapted for insertion into the body.
- medical devices include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, implants and other devices used in connection with drug-loaded polymer coatings.
- Such devices are implanted or otherwise utilized in body lumina and organs such as the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, brain, and the like.
- suitable vascular grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426.
- Vena cava filters such as those described in WO 96/12448 and WO 96/17634 may also be used in the present invention. All of foregoing documents identified by number are incorporated herein in their entireties.
- the filters that can be provided with a polymeric material/drug-agent matrix in accordance with the present invention include, for example, thrombus filters that can be placed at a selected location within the vascular system and removed when no longer required.
- a preferred location for placement of these filters is the vena cava. Filters placed in the vascular system can intercept blood clots that may otherwise travel to the lungs and result in a pulmonary embolism, a life-threatening emergency that has become increasingly common.
- an implanted vascular filter having a polymeric material/drug outer coating thereon.
- the filter has a polymeric material/paclitaxel outer coating, and most preferably, a polylactic acid/polycaprolactone copolymer/paclitaxel coating.
- the polymeric coating may also have incorporated therein or thereon any other therapeutic agent that is used for reducing the formation of, or complications due to, clot formation or neointima formation.
- agents include, but are not limited to antithrombogenic agents and thrombolytic agents and other antiproliferative agents.
- the grafts including stent grafts, that can be provided with a polymeric material/drug agent matrix in accordance with the present invention include synthetic vascular grafts that can be used for replacement of blood vessels in part or in whole.
- a typical vascular graft is a synthetic tube with each end thereof sutured to the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed.
- each end of the synthetic tube portion includes a stent that is affixed to each of the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed.
- the replacement vessel may be segment of a vessel removed from another location in the patient, such as a portion of a femoral artery or the like.
- the graft is typically tubular and may be, e.g., of a woven, knit or velour construction.
- Preferred materials for the grafts and covering material for the stent grafts include polyethylene terephthalate and polytetrafluoroethylene.
- the vascular grafts may be reinforced with, for example, helices, rings, etc. in order to provide uniform strength over the entire surface of the graft tubing.
- the materials of which such grafts are constructed are biologically compatible materials including, but not limited to, thermoplastic materials such as polyester, polytetrafluoroethylene (PTFE), silicone and polyurethanes.
- the preferred materials include polyester fibers and PTFE.
- the graft is provided with a coating of polymeric material/paclitaxel, and most preferably, the polymeric material is a copolymer of polycaprolactone and polylactic acid.
- This paclitaxel-coated graft when positioned at a desired site in the body provides an extended release of paclitaxel to the site.
- a polymeric material/drug agent matrix in accordance with the present invention may be used as an intraluminal paving system.
- the polymeric material/drug agent matrix will typically be applied directly to an interior surface of vascular or non-vascular lumina.
- An intraluminal paving system is formed, for example, by admixing a drug agent with a liquid polymer, in the absence of a solvent, to form a liquid polymer/drug agent mixture.
- the mixture is then applied directly to a luminal surface by any conventional method, such as by injecting the mixture against the luminal surface. Curing of the mixture typically occurs in-situ.
- a cross-linking or curing agent may be added to the mixture prior to application thereof to the luminal surface.
- Addition of the cross-linking or curing agent to the polymer/drug agent liquid mixture must not occur too far in advance of the application of the mixture to the luminal surface in order to avoid over-curing of the mixture prior to application thereof to the luminal surface.
- Curing may also occur in-situ by exposing the polymer/drug agent mixture, after application to the luminal surface, to radiation such as ultraviolet radiation or laser light, heat, or by contact with metabolic fluids such as water at the site where the mixture has been applied to the luminal surface.
- the drug agent is paclitaxel and the paclitaxel may be incorporated in the polymeric material alone or in combination with another drug agent.
- the polymeric material incorporating the paclitaxel and, if desired, any additional therapeutic agent(s) may be either bioabsorbable or biostable. Any of the polymers described herein that may be formulated as a liquid may be used to form the polymer/drug agent mixture for use as an intraluminal paving system.
- the polymer used to coat the medical device is provided in the form of a coating on an expandable portion of a medical device.
- the medical device After applying the drug solution to the polymer and evaporating the volatile solvent from the polymer, the medical device is inserted into a body lumen where it is positioned to a target location.
- the expandable portion of the catheter is subsequently expanded to bring the drug-impregnated polymer coating into contact with the lumen wall.
- the drug is released from the polymer as it slowly dissolves into the aqueous bodily fluids and diffuses out of the polymer. This enables administration of the drug to be site-specific, limiting the exposure of the rest of the body to the drug.
- the polymer used in the present invention is preferably capable of absorbing a substantial amount of drug solution.
- the dry polymer is typically on the order of from about 1 to about 50 microns thick.
- the thickness is preferably about 1 to 10 microns thick, and more preferably about 2 to 5 microns.
- Very thin polymer coatings e.g., of about 0.2-0.3 microns and much thicker coatings, e.g., more than 10 microns, are also possible. It is also within the scope of the present invention to apply multiple layers of polymer coating onto a medical device. Such multiple layers are of the same or different polymer materials.
- the polymer of the present invention is hydrophilic or hydrophobic, and is selected from the group consisting of polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane poly
- Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention.
- the polymer may be a protein polymer, fibrin, collage and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example.
- the preferred polymer is polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Pat. No.
- U.S. Pat. No. 5,091,205 describes medical devices coated with one or more polyisocyanates such that the devices become instantly lubricious when exposed to body fluids.
- the polymer is a copolymer of polylactic acid and polycaprolactone.
- substantially water-insoluble drug any therapeutic agent having a greater solubility in organics than in water. More specifically, such drugs have a water solubility of no greater than 1 part drug to 30 parts water, more typically no greater than 1 part drug to 1,000 parts water. Such solubilities are described as “sparingly soluble” to “very slightly soluble” in the art.
- the drug agents used in the present invention are selected from a number of drug types depending on the desired application.
- these drugs include anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, and analogues thereof; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, thymidine kinase inhibitors, and analogues thereof; anesthetic agents such as lidocaine, bupivacaine, ropivacaine, and analogues thereof; anti-coagulants; and growth factors.
- anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasal
- an anti-proliferative agent such as paclitaxel may be used in combination with another drug agent, such as an anticoagulant, anti-inflammatory, antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF, for example.
- another drug agent such as an anticoagulant, anti-inflammatory, antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF, for example.
- Paclitaxel is a preferred drug agent for use in accordance with the present invention either alone or in combination with another drug agent, as described above.
- Paclitaxel is a complex alkaloid extracted from the Pacific Yew Taxusbrevifolia Family (Family Taxacea) which has been demonstrated to have antiproliferative activity.
- paclitaxel includes the alkaloid and any pharmacologically active derivative or analog thereof.
- TAXOL® is a commercially available form of paclitaxel.
- the drug agents are dissolved in a volatile organic solvent such as, for example, ethanol, isopropanol, chloroform, acetone, pentane, hexane, or methylene chloride, to produce a drug solution.
- a volatile organic solvent such as, for example, ethanol, isopropanol, chloroform, acetone, pentane, hexane, or methylene chloride
- the preferred solvent is chloroform.
- the drug solution is then applied to the polymer.
- a volatile organic solvent typically is selected to provide drug solubilities much greater than the corresponding aqueous solubility for the substantially water-insoluble drug. Accordingly, application of the drug solution to the polymer often results in drug loadings that are orders of magnitude greater than loadings that can be achieved by application of a saturated aqueous solution of the drug to the polymer.
- the drug solution is applied to the polymer coating by any suitable means, including dipping the polymer coating into the drug solution or by applying the solution onto the coating such as by pipet or by spraying, for example.
- the amount of drug loading is controlled by regulating the time the polymer is immersed in the drug solution, the extent of polymer cross-linking, the concentration of the drug in the solution and/or the amount of polymer coating.
- the drug is incorporated directly into the polymer prior to the application of the polymer topcoat as a coating onto a medical device.
- the volatile solvent is evaporated from the coating, for example, by drying in air or in an oven.
- the release profile of the drug from the polymer coating is determined by many factors including the drug solubility, amount of drug applied and the thickness and porosity of the polymer coating.
- one or more additional layers may be applied over at least a portion of a medical device previously coated with a polymer/drug agent in accordance with the present invention.
- such an additional layer will be provided to modify or modulate the release of one or more of the drug agents in the underlying layer.
- a polymeric coating may be applied over the previously applied polymer/drug agent coating to modulate the release rate of the drug agent in that layer.
- This additional release rate-modifying or modulating layer may be applied in a subsequent coating step in a manner similar to that disclosed herein, for example by spraying a polymer solution onto the previously applied coating layer or by dipping the previously coated medical device into a solution of the polymer selected to form the modifying or modulating layer.
- any conventional adhesion promotion agent may be applied to the previously applied coating, or other treatment thereof may be conducted, in order to promote adhesion of the modifying or modulating layer to the previously applied coating.
- the polymeric material used for the modifying or modulating layer can be any of the polymers described herein.
- the polymers are those that can be formed by monomers in a gas phase that can be activated for example by radio frequency waves.
- monomers include, for example, silicone-based monomers such as cyclic or acyclic siloxanes, silanes, silylimidazoles; fluorine-based monomers such as hydrofluorocarbons; aliphatic or aromatic hydrocarbons; acrylic monomers; and combinations thereof.
- the monomer gas may have functional groups that facilitate later attachment of drug agents thereto by covalent bonding, for example.
- Any appropriate polymer for the modifying or modulating layer is preferably selected to have a porosity that provides the modifying or modulating effect as described above.
- the porosity of this polymeric material may also be modified by addition of porosigens or other porosity-effecting adjuvants that are conventionally added to polymers for this purpose.
- Other factors guiding the selection of a modulating or modifying polymer include, but are not limited to, the thickness of coating layer, the tortuosity of the polymeric material affecting the path of resistance to drug mobility within the polymeric material, the cross-linking density, drug solubility in the modulating or modifying layer, etc.
- the thickness of the modifying or modulating layer will preferably be less than 5,000 ⁇ , and more preferably in the range of from about 50-2000 ⁇ .
- a preferred modifying or modulating polymer in accordance with the present invention is a siloxane polymer formed, for example, by a plasma polymerization process. This siloxane modifying or modulating polymer is preferably applied to a medical device that has a polyurethane/drug agent coating previously applied thereto in accordance with the present invention.
- pressure can be used to increase the rate of drug transfer to the tissue.
- An increase in pressure increases the diameter of the balloon and therefore the diameter of the surrounding tissue, thereby increasing the surface area for drug transfer. The amount of drug that is delivered per unit time is therefore increased.
- the expandable portion is preferably a balloon, in which case the drug is placed in the polymer for controlled release of the drug upon expansion of the balloon against a body lumen.
- the expandable portion optionally includes a stent, mountable in a body lumen by expansion thereof.
- the catheter also optionally comprises a sheath member which is extendable over the expandable portion to inhibit release of the drug into body fluids during placement of the catheter.
- FIGS. 1 a - 1 c an embodiment for the localized delivery of substantially water-insoluble drugs to a predetermined location within the body is described.
- the drug administration method shown in FIGS. 1 a - 1 c illustrates the use of the present invention in conjunction with an angioplasty process.
- Catheter device 1 comprises a body 3 having a balloon 4 attached at its distal end.
- the balloon 4 on the catheter 3 includes a polymer coating 6 .
- drug solution 8 is impregnated into the polymer coating with the balloon in its substantially deflated state prior to insertion into the patient.
- FIG. 1 a drug solution 8 is impregnated into the polymer coating with the balloon in its substantially deflated state prior to insertion into the patient.
- the device 1 is inserted into a body lumen 2 having a region to be treated, such as an occlusion due to a deposition of plaque 5 on the lumen wall tissue 9 .
- the device 1 is moved along the vessel to position the balloon 4 at the occlusion site, as shown in FIG. 1 c .
- the lumen may be, for example, a narrow, tortuous opening through which the catheter is passed by torquing or other known techniques.
- the balloon is inflated to provide close contact between the drug-impregnated polymer coating 6 and the surrounding plaque and tissue. As water from the body penetrates into the polymer coating 6 , it begins to dissolve the drug agent, which subsequently diffuses out of the polymer coating 6 and into the surrounding plaque and tissue.
- the inflation pressure needed to expand the balloon catheter and dilate the lumen, if necessary, is typically in the range of about 1 to 20 atm.
- the balloon is formed of any suitable materials such as vinyl polymers such as polyethylene; polyesters such as polyethylene terephthalate; polyamides such as nylon; polyolefins and copolymers thereof (e.g., Selar, Pebax, Surlyn, Hytrel, etc.).
- the balloon is optionally a perfusion balloon, which allows blood to perfuse the catheter to prevent ischemia during delivery.
- a perfusion balloon is particularly preferred for long arterial delivery times and when the delivery drug is only very slightly soluble in water.
- the balloon portion 4 of catheter 3 is optionally covered by a protective sheath 7 while the instrument 1 is inserted into a body lumen 2 and positioned at a treatment region.
- the protective sheath 7 is drawn back to expose the balloon 4 .
- the sheath remains stationary while the catheter moves the coated balloon forward into the occluded region.
- the sheath 7 protects the coating and inhibits premature release of the drug.
- Such a sheath might be particularly advantageous when using drugs which are not sufficiently water-insoluble or if even minor delivery to tissue during catheter placement is a problem, e.g. for extremely toxic drugs.
- FIGS. 1 and 2 illustrate the application of the present invention to an angioplasty process
- the present invention is also used to administer drug agents to target locations where there is no occlusive formation.
- the medical device of the present invention is an implantable medical device such as a stent, covered stent, stent graft, intraluminal paving system, wire guide, cannulae, artificial limbs, joints, and other prosthetic devices.
- a stent may either balloon- or self-expandable, and is constructed of any biocompatible material.
- the grafts and covering materials for the stent grafts are made of any biocompatible material such as, for example, polyurethane, polyesters, silicone, or polytetrafluoroethylene.
- Stents are generally configured in one of two configurations: patterned or coil.
- Coil-type stents include, for example, wire stents in the form of coils, spirals or the like, with or without spines, an example of which is the subject of U.S. Pat. No. 4,886,062 (incorporated herein by reference), another example of which is the GR-II® (Cook Inc.) stent.
- Patterned stents used in accordance with a most preferred embodiment of the invention include all stents other than coil-type stents such as, for example, slotted tube stents, criss-cross tubular stents, braided stents, hexagonal stents, nets, articulated stents, and the like. Patterned stents are also generally preferred over coil stents because they provide more radial support for surrounding body lumina.
- Preferred patterned stents for use in the present invention include the NIRTM and RADIUSTM stents (SCIMED Life Systems, Inc.) as described in U.S. Pat. No.
- a stent, stent graft, vascular graft or filter in accordance with the present invention can be conducted by any medical procedure conventionally used for such implantation.
- a polymer/paclitaxel coated stent in accordance with the present invention can be fitted over the inflatable element of a balloon catheter and expanded by the balloon to force the stent into contact with the body lumen at or near a site of injury such as, for example, within an injured blood vessel.
- any blood vessel including arteries, veins and capillaries may be treated in accordance with the present invention.
- These blood vessels may be in or near any organ in the human or mammalian body.
- a patterned stent having a polymer/paclitaxel coating is used to prevent or inhibit proliferative disease.
- proliferative disease means any disease or disorder including cancers, malignancies, benign growths and other conditions that result from hyperactivity or hyperplasia of somatic cells, and includes restenosis and vascular hyperplasia such as neointimal hyperplasia. Such proliferative diseases may occur in vascular and other luminal or non-luminal regions of the body.
- FIG. 10 shows the release rate of paclitaxel obtained with a stent in accordance with the present invention.
- paclitaxel is released from a polymer/paclitaxel coated stent for a time period of at least about 28 days after implantation of stent at the desired location within the body.
- the patterned stent is coated with an outer coating of polymer/paclitaxel such that the amount of paclitaxel is sufficient to prevent, decrease, eliminate or modify cellular proliferation associated with proliferative disease or disorder.
- the amount of paclitaxel sufficient to inhibit or prevent proliferative disease will vary according to the size of the patterned stents, but is generally in the range of from about 50 ⁇ g to 500 ⁇ g per stent.
- a 2 mg/ml solution of paclitaxel is prepared in chloroform.
- the solution is gently agitated until the paclitaxel is completely dissolved.
- the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating and inflated to 2 atm.
- a total of 100 ⁇ l of solution, and hence 200 ⁇ g of paclitaxel, is applied to the catheter.
- the balloon catheter is then dried in air for 30 minutes and in a vacuum oven for 48 hours at 50° C. to evaporate the chloroform.
- the catheter is then immersed in a solution of 1% dimethyl sulfoxide (DMSO) and phosphate buffered saline (PBS) having a pH of 7.4 for in-vitro drug release.
- DMSO dimethyl sulfoxide
- PBS phosphate buffered saline
- Solutions containing 1.5 mg/ml and 200 ⁇ g/ml of dexamethasone in chloroform are prepared by gently agitating until the dexamethasone is completely dissolved.
- the solutions are separately applied via dripping to separate balloon catheters having polyacrylic acid-based coatings and inflated to 2 atm. A total of 100 ⁇ l of each solution is applied to each respective catheter, corresponding to dexamethasone loadings of 1.5 mg and 200 ⁇ g, respectively.
- the balloon catheters are then dried in a vacuum oven for 2 hours at 50° C. to evaporate the chloroform solvent.
- dexamethasone is added directly to the polymer used to coat the balloon catheters.
- Dexamethasone is weighed out into 0.05 g, 0.1 g, and 0.2 g samples, each of which is each added to 1 ml lots of polymer topcoat solution containing polyacrylic acid, methyl ethyl ketone, dimethyl formamide, and t-butyl alcohol.
- the dexamethasone samples are mixed with the polymer topcoat solutions until completely dissolved.
- Estradiol is provided in both water-soluble and substantially water-insoluble forms.
- Water-soluble estradiol is applied to a balloon catheter coated with a polyacrylic acid-based coating by i) preparing a 10 mg/ml solution of water-soluble estradiol in deionized, ultra-filtered water; and ii) placing the balloon catheter, inflated to 2 atm, into 200 ⁇ l of the solution for 20 minutes.
- Water-insoluble estradiol is applied to a balloon catheter coated with a polyacrylic-acid based coating by i) preparing a 10 mg/ml solution of substantially water-insoluble estradiol in methanol; and ii) dripping 100 ⁇ l of the solution onto the balloon catheter.
- the cumulative amount of estradiol released from each catheter yields the data shown in FIGS. 7 a and 7 b.
- a 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared.
- a total of 50 ⁇ l of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating.
- the paclitaxel from the coated balloon catheter is then released in-vivo to porcine arteries. After release for a predetermined amount of time, the paclitaxel remaining in the coating is extracted using two sequential ethanol washes.
- the amount of paclitaxel released in the pig bloodstream, as calculated from the amount of paclitaxel loaded into the coating minus that extracted from the coating after delivery, is shown in Table II.
- Amount of paclitaxel released into pig bloodstream from an impregnated, polyacrylic acid-based coated balloon catheter as a function of delivery time.
- a 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared.
- a total of 50 ⁇ l of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating.
- the coated balloon catheter is then delivered to an explanted porcine artery for 15 minutes.
- the paclitaxel remaining in the coating is extracted using two sequential ethanol washes.
- the delivered paclitaxel is extracted from the vessel, also by using two sequential ethanol washes.
- the vessel is placed in tissue solvent and counted for paclitaxel. Using these extraction methods, at least 80% of the paclitaxel loaded onto the balloon catheter is recovered, as shown in Table III.
- Slotted tube stainless steel stents are coated with polyurethane by spraying a 1 wt % solution of CHRONOFLEX® polyurethane (made by CT Biomaterials) in tetrahydrofuran directly onto the stent surface.
- the coated stents are dried in a vacuum oven for three hours at 70° C.
- Each polyurethane coated stent is placed in a vial, which is filled to maximum volume (1.5 ml) with a solution of paclitaxel in ethanol, and sealed.
- the stent is stored in the vial for three days at room temperature.
- the stent is then removed from the vial and dried for one hour at 65° C.
- Paclitaxel Paclitaxel Coating ⁇ g Paclitaxel Sample conc. content Wt. per # (mg/ml) ( ⁇ g) ( ⁇ g) ⁇ g coating 1 10 44.8 796 0.06 2 10 88.2 859 0.10 3 20 151.2 718 0.21 4 20 127.6 702 0.18 5 30 157.1 736 0.21 6 30 144.3 629 0.23
- paclitaxel loading is relatively independent of paclitaxel concentration above 20 mg/ml, assuming equilibrium is attained in the three-day period. Nevertheless, the 30 mg/ml paclitaxel concentration is chosen for release studies as it produces the maximum paclitaxel loading (21-23%), while still being sufficiently below the saturation concentration for paclitaxel in ethanol (39 mg/ml).
- Paclitaxel Paclitaxel Coating ⁇ g Paclitaxel Sample conc. content Wt. per # (mg/ml) ( ⁇ g) ( ⁇ g) ⁇ g coating 1 30 111.7 676 0.17 2 30 50 627 0.08 3 30 45.3 612 0.07 4 30 37.4 602 0.06
- the remaining three stents are immersed in a solution of phosphate buffered saline solution having pH 7.4 at 37° C. Cumulative release as a function of time is presented in FIG. 8 .
- Nylon balloons are coated with polyurethane by dipping into a 9 wt % solution of CHRONOFLEX® polyurethane in dimethylacetamide. The balloons are dried in a vacuum oven overnight at 50° C.
- Each polyurethane coated balloon is loaded with paclitaxel either by dipping the coated balloon into a paclitaxel and ethanol solution or by dripping a known volume of a paclitaxel and ethanol solution onto the balloon surface.
- a stock saturated solution of paclitaxel in ethanol is prepared.
- the polyurethane-coated balloon is inflated and submerged in the paclitaxel stock solution in a tube.
- the tube and balloon are well-sealed to prevent solvent evaporation.
- the ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “dip-coated” balloons are prepared in this fashion.
- a stock solution of paclitaxel having a concentration of 10 mg/ml prepared. Twenty ml of this paclitaxel stock solution are then pipetted onto an inflated polyurethane-coated balloon, providing a total mass of 200 mg of paclitaxel per balloon. Afterwards, ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “drip-coated” balloons are prepared in this fashion.
- the paclitaxel content of the dip-coated balloons is found to be 1093+/ ⁇ 439 mg, while the drip-coated balloons are found to have 215+/ ⁇ 11 ⁇ g paclitaxel.
- nylon balloons are coated with paclitaxel/polyurethane by dipping the balloons into a dispersion of 14.5 wt % BAHYDROL® polyurethane (made by Bayer) and 2.6 wt % paclitaxel in a mixture of 73.6 vol % N-methylpyrrolidinone and 26.4 vol % water. Balloons are dried in a vacuum oven overnight at 50° C. The dried coatings contain 15% paclitaxel by weight. Nine balloons are formed. Seven balloons are tested for paclitaxel loading yielding an average of 196
- PLA/PCL copolymer obtained from Birmingham Polymers, Inc., Birmingham, Ala. was dissolved in chloroform.
- Paclitaxel obtained from Hauser, Inc. was then dissolved in the chloroform to form a solution having a 70/30 weight ratio of copolymer/paclitaxel.
- the solution was then sprayed onto the surface of a 9 mm long balloon-expandable stainless steel NIR® stent obtained from Medinol, Inc., Tel Aviv, Israel. Substantially all exposed surfaces of the stent were covered with the solution.
- the stent was then dried in a vacuum oven at 50° C. for approximately 2 hr. and a matrix of PLA/PCL copolymer having 200 ⁇ g of paclitaxel incorporated therein was thus formed as a coating on the stent.
- the paclitaxel component of the matrix comprised approximately 30% by weight of the matrix.
- a stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a porcine coronary artery. In vitro, the stent delivered 2-3 ⁇ g/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 50% reduction in the occurrence of neointimal hyperplasia was observed.
- a stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 ⁇ g/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 70% reduction in the occurrence of neointimal hyperplasia was observed.
- a stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 ⁇ g/day of paclitaxel over a period of 56 days. In comparison to the same stent having no coating, after 56 days, a 60% reduction in the occurrence of neointimal hyperplasia was observed.
- a filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10.
- the filter is sized and constructed to be compressed and passed through the vasculature of a patient to be anchored against an inner wall surface of a blood vessel for capturing blood clots in a blood stream passing therethrough.
- the filter is described in International Application No. WO 96/17634.
- a filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10.
- the filter is also adapted for placement in a blood vessel for capturing blood clots in a blood stream passing therethrough.
- This filter is provided with struts that minimize the risk of vessel damage if the vessel is compressed asymmetrically.
- the filter is described in International Application No. WO 96/12448.
- a woven synthetic vascular graft for replacement of a segment a blood vessel is coated with a PLA/PCL copolymer/paclitaxel matrix in a manner substantially as set forth in Example 10.
- the vascular graft is ravel-resistant due to inclusion of a fusible component and self-supporting due to inclusion of a stiffening component.
- the vascular graft is described in U.S. Pat. No. 5,509,931.
- any suitable polymer may be used for the polymer coating
- any suitable drying time periods and temperatures may be used
- any suitable organic solvent may be used
- any suitable method for applying the polymer coatings to the medical devices may be used
- any suitable method for applying the drugs to the polymer coatings may be used
- any suitable water-insoluble analogue of the disclosed drugs may be used
- any suitable drug loading concentrations may be used.
- the present invention provides a previously unknown method and medical device for the localized delivery of substantially water-insoluble drugs.
- the present invention provides, in one embodiment, a paclitaxel/polymer coated stent which has an extended release rate of from about 0.2 to about 7 ⁇ g per day, preferably in the range of from about 0.5 to about 5 ⁇ g per lay over an extended period of at least about 28 days.
- a polymer/paclitaxel coated non-coiled stent which has an extended release rate of paclitaxel and which reduces neointima formation in injured blood vessels and other body lumens into which it is placed.
- the extended release rate is effective to prevent, decrease, eliminate, or modify cellular proliferation associated with neointima formation and/or other proliferative disease or disorder.
Abstract
A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a polymer coating. Incorporated in the polymer coating is a solution of at least one substantially water-insoluble drug in a volatile organic solvent. The medical device is positioned to a desired target location within the body, whereupon the drug diffuses out of the polymer coating.
Description
- This application is a Division of application Ser. No. 11/833,717, filed Aug. 3, 2007, which is a Division of application Ser. No. 11/188,850, filed Jul. 26, 2005, now abandoned, which is a Continuation of application Ser. No. 09/978,763, filed Oct. 18, 2001, now abandoned, which is a Continuation of application Ser. No. 09/172,026, filed Oct. 14, 1998, now U.S. Pat. No. 6,306,166, which is a Continuation-in-part of application Ser. No. 09/133,603, filed Aug. 13, 1998, now abandoned, which is a Continuation-in-part of application Ser. No. 08/910,136, filed Aug. 13, 1997, now abandoned, the contents of each or which are hereby incorporated by reference.
- The invention relates to methods and devices for the localized delivery of substantially water-insoluble drug agents within the body.
- The systemic administration of drug agents, such as by transoral or intravenous means, treats the body as a whole even though the disease to be treated may be localized. In such a case, systemic administration may not be desirable because, for example, the drug agents may have unwanted effects on parts of the body which are not to be treated, or because treatment of the diseased part of the body requires a high concentration of drug agent that may not be achievable by systemic administration.
- It is therefore often desirable to administer drug agents at a localized site within the body. Common examples include cases of localized disease or occluded body lumens. Various methods have been proposed for such localized drug administration. For example, U.S. Pat. No. 5,304,121, hereby incorporated by reference, discloses a method of delivering water-soluble drugs to tissue at desired locations of a body lumen wall. The method generally includes the steps of impregnating a hydrogel polymer on an expandable catheter with an aqueous drug solution, inserting the catheter into a blood vessel to a desired location, and expanding the catheter against the surrounding tissue allowing the release of the drug to the tissue. This method of localized drug delivery using hydrogel polymer impregnation has a limitation of being applicable to drug agents which are dissolved in water at concentrations sufficient for therapeutic gel loading levels. There thus exists a need for a method and apparatus for the localized delivery of drug agents within the body, where the drug agents are substantially water-insoluble. Moreover, there exists a need for a method and implantable device that provides a sustained release of such substantially water-insoluble drug agents over a time frame effective to inhibit proliferative disease.
- One objective of the present invention is to provide a method and apparatus for the localized delivery of substantially water-insoluble drug agents to predetermined locations within the human body.
- A further objective of the present invention is to provide a method and apparatus to facilitate gradual, localized release of drug agents at predetermined locations within the human body.
- A further objective of the invention is to administer drug agents by diffusion directly into the tissue requiring treatment. The drug is preferably applied in a manner that does not further injure the tissue to be treated, and administration is selectively and evenly distributed over the treated area such that the drug can be taken up by the tissue, without, for example, being washed away by body fluids.
- The present invention provides methods and medical devices for the localized delivery of substantially water-insoluble drugs agents.
- A particular embodiment of the present invention features a catheter and method for delivering substantially water-insoluble drug agents to tissue at a desired location along body lumen walls. The catheter is constructed for insertion in a body lumen and has a catheter shaft and an expandable portion mounted on the catheter shaft. The expandable portion is expandable to fill the cross-section of the body lumen. At least a portion of the exterior surface of the expandable portion is defined by a polymer coating. Incorporated into the polymer coating is at least one substantially water-insoluble drug. The catheter is positioned to a desired target location within the body, whereupon the polymer coating absorbs water, thus dissolving the drug and resulting in the diffusion of the drug out of the polymer coating. The polymer and drug are selected to allow controlled release of a desired dosage of the drug from the polymer.
- Another particular embodiment of the present invention features a stent for the localized delivery of substantially water-insoluble drug agents to tissue at a desired location along body lumen walls. The stent is at least partially coated with a polymer coating having at least one substantially water-insoluble drug therein. The stent configuration, polymer and drug are selected to allow for the controlled release dosage and release rate of the drug from the polymer.
- In a most preferred embodiment, the stent is a patterned stent for the localized delivery of paclitaxel to tissue at a desired location along body lumen walls. The stent is at least partially coated with a polymer/paclitaxel matrix that provides sustained release of paclitaxel at the desired site within the lumen wall.
- In another aspect of the invention, there is provided a method for preventing or inhibiting proliferative disease in a patient comprising implanting a patterned stent comprising an outer coating of polymer/paclitaxel at a site of cellular proliferation, wherein the paclitaxel is released from the outer coating at a release rate and for a period of time sufficient to inhibit or prevent cellular proliferation at the site.
-
FIG. 1 a shows one embodiment of the present invention in which a drug solution is impregnated into a polymer-coated balloon catheter. -
FIG. 1 b shows the insertion of a polymer-coated balloon catheter into a body lumen, in accordance with the present invention. -
FIG. 1 c shows the expansion of a polymer-coated balloon catheter at an occlusion site within a body lumen, in accordance with the present invention. -
FIG. 2 shows a drug delivery balloon catheter embodiment of the present invention including a sheath for covering the catheter as it is being moved through a vessel toward the occlusion to be treated. -
FIGS. 3 a and 3 b show the release profile of paclitaxel from a balloon catheter having a polyacrylic acid-based coating for up to 50 and 5000 minutes, respectively, in accordance with the present invention. -
FIGS. 4 a and 4 b show the release profile of dexamethasone from a balloon catheter having a polyacrylic acid-based coating for up to 30 and 400 minutes, respectively, in accordance with the present invention. -
FIG. 5 shows the release profiles of molsidomine from various balloon catheters having a polyacrylic acid-based coating for up to 5 minutes, in accordance with the present invention. -
FIG. 6 shows the release profiles of dexamethasone from various balloon catheters having a polyacrylic acid-based coating for up to 450 minutes, in accordance with the present invention. -
FIGS. 7 a and 7 b show the release profiles of water-soluble and substantially water-insoluble estradiol from balloon catheters having a polyacrylic acid-based coatings for up to 10 and 200 minutes, respectively, in accordance with the present invention. -
FIG. 8 shows the release profile of paclitaxel for up to 10 days from polyurethane coated stents dipped in 30 mg/ml paclitaxel in ethanol for 3 days, in accordance with the present invention. -
FIG. 9 shows the release profiles of paclitaxel from various polyurethane-coated balloon catheters for up to 2 hours, in accordance with the present invention. -
FIG. 10 shows the cumulative release profile of paclitaxel over a time frame of days. This figure shows the cumulative release of paclitaxel for delivery rates of 5 μg/day and 0.5 μg/day. - The present invention provides methods and medical devices for the localized delivery of one or more substantially water-insoluble drug agents to predetermined locations within the human body, such as within the vascular system, urinary tract, prostate, esophagus, colon, brain, etc.
- In accordance with an embodiment of the invention, a substantially water-insoluble drug agent is dissolved in a volatile organic solvent. “Organic solvent” is intended to mean a singular organic solvent or a solvent mixture having at least one organic component. The solvent mixture also includes mixtures of water with miscible organic solvents. The drug solution is then applied to a polymer coating on a medical device that is adapted for insertion into the body. Examples of such medical devices include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, implants and other devices used in connection with drug-loaded polymer coatings. Such devices are implanted or otherwise utilized in body lumina and organs such as the coronary vasculature, esophagus, trachea, colon, biliary tract, urinary tract, prostate, brain, and the like. Examples of suitable vascular grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426. Vena cava filters such as those described in WO 96/12448 and WO 96/17634 may also be used in the present invention. All of foregoing documents identified by number are incorporated herein in their entireties.
- The filters that can be provided with a polymeric material/drug-agent matrix in accordance with the present invention include, for example, thrombus filters that can be placed at a selected location within the vascular system and removed when no longer required. A preferred location for placement of these filters is the vena cava. Filters placed in the vascular system can intercept blood clots that may otherwise travel to the lungs and result in a pulmonary embolism, a life-threatening emergency that has become increasingly common. In one embodiment of the present invention there is provided such an implanted vascular filter having a polymeric material/drug outer coating thereon. In a most preferred embodiment, the filter has a polymeric material/paclitaxel outer coating, and most preferably, a polylactic acid/polycaprolactone copolymer/paclitaxel coating. The polymeric coating may also have incorporated therein or thereon any other therapeutic agent that is used for reducing the formation of, or complications due to, clot formation or neointima formation. Such agents, include, but are not limited to antithrombogenic agents and thrombolytic agents and other antiproliferative agents.
- Further examples of filters that may be provided with the polymeric material/drug coating in accordance with present invention include, e.g., those described in International Application No. WO 96/17634 and International Application No. WO 96/12448, both of which are herein incorporated by reference.
- The grafts, including stent grafts, that can be provided with a polymeric material/drug agent matrix in accordance with the present invention include synthetic vascular grafts that can be used for replacement of blood vessels in part or in whole. A typical vascular graft is a synthetic tube with each end thereof sutured to the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. In a typical stent graft, each end of the synthetic tube portion includes a stent that is affixed to each of the remaining ends of a blood vessel from which a diseased or otherwise damaged portion has been removed. Alternatively, in a stent graft, the replacement vessel may be segment of a vessel removed from another location in the patient, such as a portion of a femoral artery or the like. In the case of a synthetic graft, the graft is typically tubular and may be, e.g., of a woven, knit or velour construction. Preferred materials for the grafts and covering material for the stent grafts include polyethylene terephthalate and polytetrafluoroethylene. The vascular grafts may be reinforced with, for example, helices, rings, etc. in order to provide uniform strength over the entire surface of the graft tubing. The materials of which such grafts are constructed are biologically compatible materials including, but not limited to, thermoplastic materials such as polyester, polytetrafluoroethylene (PTFE), silicone and polyurethanes. The preferred materials include polyester fibers and PTFE.
- Examples of other suitable grafts are described in U.S. Pat. Nos. 5,509,931, 5,527,353, and 5,556,426, all of which are herein incorporated by reference. In a most preferred embodiment of the invention, the graft is provided with a coating of polymeric material/paclitaxel, and most preferably, the polymeric material is a copolymer of polycaprolactone and polylactic acid. This paclitaxel-coated graft, when positioned at a desired site in the body provides an extended release of paclitaxel to the site.
- A polymeric material/drug agent matrix in accordance with the present invention may be used as an intraluminal paving system. In such intraluminal paving systems as are known in the art, the polymeric material/drug agent matrix will typically be applied directly to an interior surface of vascular or non-vascular lumina. An intraluminal paving system is formed, for example, by admixing a drug agent with a liquid polymer, in the absence of a solvent, to form a liquid polymer/drug agent mixture. The mixture is then applied directly to a luminal surface by any conventional method, such as by injecting the mixture against the luminal surface. Curing of the mixture typically occurs in-situ. To facilitate curing, a cross-linking or curing agent may be added to the mixture prior to application thereof to the luminal surface. Addition of the cross-linking or curing agent to the polymer/drug agent liquid mixture must not occur too far in advance of the application of the mixture to the luminal surface in order to avoid over-curing of the mixture prior to application thereof to the luminal surface. Curing may also occur in-situ by exposing the polymer/drug agent mixture, after application to the luminal surface, to radiation such as ultraviolet radiation or laser light, heat, or by contact with metabolic fluids such as water at the site where the mixture has been applied to the luminal surface. In a preferred intraluminal paving system in accordance with the invention, the drug agent is paclitaxel and the paclitaxel may be incorporated in the polymeric material alone or in combination with another drug agent. In intraluminal paving systems in accordance with a preferred embodiment of the present invention, the polymeric material incorporating the paclitaxel and, if desired, any additional therapeutic agent(s), may be either bioabsorbable or biostable. Any of the polymers described herein that may be formulated as a liquid may be used to form the polymer/drug agent mixture for use as an intraluminal paving system.
- In a preferred embodiment, the polymer used to coat the medical device is provided in the form of a coating on an expandable portion of a medical device. After applying the drug solution to the polymer and evaporating the volatile solvent from the polymer, the medical device is inserted into a body lumen where it is positioned to a target location. In the case of a balloon catheter, the expandable portion of the catheter is subsequently expanded to bring the drug-impregnated polymer coating into contact with the lumen wall. The drug is released from the polymer as it slowly dissolves into the aqueous bodily fluids and diffuses out of the polymer. This enables administration of the drug to be site-specific, limiting the exposure of the rest of the body to the drug.
- The polymer used in the present invention is preferably capable of absorbing a substantial amount of drug solution. When applied as a coating on a medical device in accordance with the present invention, the dry polymer is typically on the order of from about 1 to about 50 microns thick. In the case of a balloon catheter, the thickness is preferably about 1 to 10 microns thick, and more preferably about 2 to 5 microns. Very thin polymer coatings, e.g., of about 0.2-0.3 microns and much thicker coatings, e.g., more than 10 microns, are also possible. It is also within the scope of the present invention to apply multiple layers of polymer coating onto a medical device. Such multiple layers are of the same or different polymer materials.
- The polymer of the present invention is hydrophilic or hydrophobic, and is selected from the group consisting of polycarboxylic acids, cellulosic polymers, including cellulose acetate and cellulose nitrate, gelatin, polyvinylpyrrolidone, cross-linked polyvinylpyrrolidone, polyanhydrides including maleic anhydride polymers, polyamides, polyvinyl alcohols, copolymers of vinyl monomers such as EVA, polyvinyl ethers, polyvinyl aromatics, polyethylene oxides, glycosaminoglycans, polysaccharides, polyesters including polyethylene terephthalate, polyacrylamides, polyethers, polyether sulfone, polycarbonate, polyalkylenes including polypropylene, polyethylene and high molecular weight polyethylene, halogenated polyalkylenes including polytetrafluoroethylene, polyurethanes, polyorthoesters, proteins, polypeptides, silicones, siloxane polymers, polylactic acid, polyglycolic acid, polycaprolactone, polyhydroxybutyrate valerate and blends and copolymers thereof as well as other biodegradable, bioabsorbable and biostable polymers and copolymers. Coatings from polymer dispersions such as polyurethane dispersions (BAYHDROL®, etc.) and acrylic latex dispersions are also within the scope of the present invention. The polymer may be a protein polymer, fibrin, collage and derivatives thereof, polysaccharides such as celluloses, starches, dextrans, alginates and derivatives of these polysaccharides, an extracellular matrix component, hyaluronic acid, or another biologic agent or a suitable mixture of any of these, for example. In one embodiment of the invention, the preferred polymer is polyacrylic acid, available as HYDROPLUS® (Boston Scientific Corporation, Natick, Mass.), and described in U.S. Pat. No. 5,091,205, the disclosure of which is hereby incorporated herein by reference. U.S. Pat. No. 5,091,205 describes medical devices coated with one or more polyisocyanates such that the devices become instantly lubricious when exposed to body fluids. In a most preferred embodiment of the invention, the polymer is a copolymer of polylactic acid and polycaprolactone.
- By “substantially water-insoluble drug” is meant any therapeutic agent having a greater solubility in organics than in water. More specifically, such drugs have a water solubility of no greater than 1 part drug to 30 parts water, more typically no greater than 1 part drug to 1,000 parts water. Such solubilities are described as “sparingly soluble” to “very slightly soluble” in the art.
- The drug agents used in the present invention are selected from a number of drug types depending on the desired application. For example, these drugs include anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, and analogues thereof; antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, thymidine kinase inhibitors, and analogues thereof; anesthetic agents such as lidocaine, bupivacaine, ropivacaine, and analogues thereof; anti-coagulants; and growth factors.
- The drug agents useful in accordance with the present invention may be used singly or in combination. For example, an anti-proliferative agent such as paclitaxel may be used in combination with another drug agent, such as an anticoagulant, anti-inflammatory, antithrombogenic, thrombolytic, nitric oxide-containing polymer, or a vascular cell promoter such as VEGF, for example.
- Paclitaxel is a preferred drug agent for use in accordance with the present invention either alone or in combination with another drug agent, as described above. Paclitaxel is a complex alkaloid extracted from the Pacific Yew Taxusbrevifolia Family (Family Taxacea) which has been demonstrated to have antiproliferative activity. As used herein, paclitaxel includes the alkaloid and any pharmacologically active derivative or analog thereof. Thus paclitaxel includes naturally occurring forms and derivatives thereof and synthetic and semi-synthetic forms thereof TAXOL® is a commercially available form of paclitaxel.
- In accordance with the present invention, the drug agents are dissolved in a volatile organic solvent such as, for example, ethanol, isopropanol, chloroform, acetone, pentane, hexane, or methylene chloride, to produce a drug solution. In the case of paclitaxel the preferred solvent is chloroform. The drug solution is then applied to the polymer. A volatile organic solvent typically is selected to provide drug solubilities much greater than the corresponding aqueous solubility for the substantially water-insoluble drug. Accordingly, application of the drug solution to the polymer often results in drug loadings that are orders of magnitude greater than loadings that can be achieved by application of a saturated aqueous solution of the drug to the polymer.
- The drug solution is applied to the polymer coating by any suitable means, including dipping the polymer coating into the drug solution or by applying the solution onto the coating such as by pipet or by spraying, for example. In the former method, the amount of drug loading is controlled by regulating the time the polymer is immersed in the drug solution, the extent of polymer cross-linking, the concentration of the drug in the solution and/or the amount of polymer coating. In another embodiment of the invention, the drug is incorporated directly into the polymer prior to the application of the polymer topcoat as a coating onto a medical device.
- After applying the drug solution to the polymer coating, the volatile solvent is evaporated from the coating, for example, by drying in air or in an oven.
- The release profile of the drug from the polymer coating is determined by many factors including the drug solubility, amount of drug applied and the thickness and porosity of the polymer coating.
- In a preferred embodiment of the present invention, one or more additional layers may be applied over at least a portion of a medical device previously coated with a polymer/drug agent in accordance with the present invention. Desirably, such an additional layer will be provided to modify or modulate the release of one or more of the drug agents in the underlying layer. For example, a polymeric coating may be applied over the previously applied polymer/drug agent coating to modulate the release rate of the drug agent in that layer. This additional release rate-modifying or modulating layer may be applied in a subsequent coating step in a manner similar to that disclosed herein, for example by spraying a polymer solution onto the previously applied coating layer or by dipping the previously coated medical device into a solution of the polymer selected to form the modifying or modulating layer. However, other methods for applying polymeric materials to substrates, including, for example, in-situ polymerization methods such as plasma polymerization may also be used to provide the additional release rate-modifying or modulating polymeric layer. Such other application processes included within the scope of the present invention are those that will not detrimentally affect the previously applied layer, including the drug agent(s) incorporated therein or thereon. The additional layer may also include one or more additional drug agents including any of the drug agents incorporated into the underlying polymer/drug agent coating layer. Prior to application of the modifying or modulating layer, any conventional adhesion promotion agent may be applied to the previously applied coating, or other treatment thereof may be conducted, in order to promote adhesion of the modifying or modulating layer to the previously applied coating. Where the modifying or modulating layer is applied in a manner similar to the underlying layer, the polymeric material used for the modifying or modulating layer can be any of the polymers described herein. Where such polymeric material is applied, for example, by plasma polymerization, the polymers are those that can be formed by monomers in a gas phase that can be activated for example by radio frequency waves. Such monomers include, for example, silicone-based monomers such as cyclic or acyclic siloxanes, silanes, silylimidazoles; fluorine-based monomers such as hydrofluorocarbons; aliphatic or aromatic hydrocarbons; acrylic monomers; and combinations thereof. The monomer gas may have functional groups that facilitate later attachment of drug agents thereto by covalent bonding, for example. Any appropriate polymer for the modifying or modulating layer is preferably selected to have a porosity that provides the modifying or modulating effect as described above. The porosity of this polymeric material may also be modified by addition of porosigens or other porosity-effecting adjuvants that are conventionally added to polymers for this purpose. Other factors guiding the selection of a modulating or modifying polymer include, but are not limited to, the thickness of coating layer, the tortuosity of the polymeric material affecting the path of resistance to drug mobility within the polymeric material, the cross-linking density, drug solubility in the modulating or modifying layer, etc. The thickness of the modifying or modulating layer will preferably be less than 5,000 Å, and more preferably in the range of from about 50-2000 Å. A preferred modifying or modulating polymer in accordance with the present invention is a siloxane polymer formed, for example, by a plasma polymerization process. This siloxane modifying or modulating polymer is preferably applied to a medical device that has a polyurethane/drug agent coating previously applied thereto in accordance with the present invention.
- When an expandable member such as a balloon catheter is used to administer the drug, pressure can be used to increase the rate of drug transfer to the tissue. An increase in pressure increases the diameter of the balloon and therefore the diameter of the surrounding tissue, thereby increasing the surface area for drug transfer. The amount of drug that is delivered per unit time is therefore increased.
- When an expandable catheter is chosen as the medical device of the present invention, the expandable portion is preferably a balloon, in which case the drug is placed in the polymer for controlled release of the drug upon expansion of the balloon against a body lumen. The expandable portion optionally includes a stent, mountable in a body lumen by expansion thereof. The catheter also optionally comprises a sheath member which is extendable over the expandable portion to inhibit release of the drug into body fluids during placement of the catheter.
- Referring now to
FIGS. 1 a-1 c, an embodiment for the localized delivery of substantially water-insoluble drugs to a predetermined location within the body is described. The drug administration method shown inFIGS. 1 a-1 c illustrates the use of the present invention in conjunction with an angioplasty process.Catheter device 1 comprises abody 3 having aballoon 4 attached at its distal end. Theballoon 4 on thecatheter 3 includes apolymer coating 6. As shown inFIG. 1 a,drug solution 8 is impregnated into the polymer coating with the balloon in its substantially deflated state prior to insertion into the patient. As shown inFIG. 1 b, after the volatile solvent is evaporated, thedevice 1 is inserted into abody lumen 2 having a region to be treated, such as an occlusion due to a deposition ofplaque 5 on thelumen wall tissue 9. Thedevice 1 is moved along the vessel to position theballoon 4 at the occlusion site, as shown inFIG. 1 c. The lumen may be, for example, a narrow, tortuous opening through which the catheter is passed by torquing or other known techniques. As shown inFIG. 1 c, the balloon is inflated to provide close contact between the drug-impregnatedpolymer coating 6 and the surrounding plaque and tissue. As water from the body penetrates into thepolymer coating 6, it begins to dissolve the drug agent, which subsequently diffuses out of thepolymer coating 6 and into the surrounding plaque and tissue. - During drug administration, a substantial amount of the drug contained in the polymer coating is diffused into the affected area. The inflation pressure needed to expand the balloon catheter and dilate the lumen, if necessary, is typically in the range of about 1 to 20 atm. The balloon is formed of any suitable materials such as vinyl polymers such as polyethylene; polyesters such as polyethylene terephthalate; polyamides such as nylon; polyolefins and copolymers thereof (e.g., Selar, Pebax, Surlyn, Hytrel, etc.). The balloon is optionally a perfusion balloon, which allows blood to perfuse the catheter to prevent ischemia during delivery. A perfusion balloon is particularly preferred for long arterial delivery times and when the delivery drug is only very slightly soluble in water.
- Referring to the embodiment of the invention illustrated in
FIG. 2 , theballoon portion 4 ofcatheter 3 is optionally covered by aprotective sheath 7 while theinstrument 1 is inserted into abody lumen 2 and positioned at a treatment region. As thecoated balloon 4 is positioned atoccluded site 5, theprotective sheath 7 is drawn back to expose theballoon 4. In an alternative embodiment, the sheath remains stationary while the catheter moves the coated balloon forward into the occluded region. Thesheath 7 protects the coating and inhibits premature release of the drug. Such a sheath might be particularly advantageous when using drugs which are not sufficiently water-insoluble or if even minor delivery to tissue during catheter placement is a problem, e.g. for extremely toxic drugs. - Although
FIGS. 1 and 2 illustrate the application of the present invention to an angioplasty process, the present invention is also used to administer drug agents to target locations where there is no occlusive formation. - In other embodiments, the medical device of the present invention is an implantable medical device such as a stent, covered stent, stent graft, intraluminal paving system, wire guide, cannulae, artificial limbs, joints, and other prosthetic devices. Where a stent is used it may either balloon- or self-expandable, and is constructed of any biocompatible material. The grafts and covering materials for the stent grafts are made of any biocompatible material such as, for example, polyurethane, polyesters, silicone, or polytetrafluoroethylene.
- Stents are generally configured in one of two configurations: patterned or coil. Coil-type stents include, for example, wire stents in the form of coils, spirals or the like, with or without spines, an example of which is the subject of U.S. Pat. No. 4,886,062 (incorporated herein by reference), another example of which is the GR-II® (Cook Inc.) stent. Patterned stents used in accordance with a most preferred embodiment of the invention include all stents other than coil-type stents such as, for example, slotted tube stents, criss-cross tubular stents, braided stents, hexagonal stents, nets, articulated stents, and the like. Patterned stents are also generally preferred over coil stents because they provide more radial support for surrounding body lumina. Preferred patterned stents for use in the present invention include the NIR™ and RADIUS™ stents (SCIMED Life Systems, Inc.) as described in U.S. Pat. No. 5,733,303 and WO 96/26689 (both of which are incorporated herein by reference); the WALLSTENT® (Schneider Inc.) as described in U.S. Pat. Nos. 4,655,771 and 5,061,275 (both of which are incorporated herein by reference); and the SYMPHONY® stent (Boston Scientific Corp.) as described in U.S. Pat. No. 5,540,712 (incorporated herein by reference). The stents and stent grafts described in U.S. Pat. Nos. 5,766,237, 5,681,356, 5,522,881 and 5,776,180 (each of which is incorporated herein by reference) and the polymer stents described in U.S. Pat. No. 5,769,883 (incorporated herein by reference) are also within the scope of the present invention.
- The implantation of a stent, stent graft, vascular graft or filter in accordance with the present invention can be conducted by any medical procedure conventionally used for such implantation. In the case of a stent, a polymer/paclitaxel coated stent in accordance with the present invention can be fitted over the inflatable element of a balloon catheter and expanded by the balloon to force the stent into contact with the body lumen at or near a site of injury such as, for example, within an injured blood vessel.
- Where the medical device in accordance with the present invention is, e.g., a catheter, stent, graft, filter, etc., or any other device used in the vascular system, any blood vessel including arteries, veins and capillaries may be treated in accordance with the present invention. These blood vessels may be in or near any organ in the human or mammalian body.
- In a most preferred embodiment of the invention, a patterned stent having a polymer/paclitaxel coating is used to prevent or inhibit proliferative disease. As used herein, “proliferative disease” means any disease or disorder including cancers, malignancies, benign growths and other conditions that result from hyperactivity or hyperplasia of somatic cells, and includes restenosis and vascular hyperplasia such as neointimal hyperplasia. Such proliferative diseases may occur in vascular and other luminal or non-luminal regions of the body.
- The inventors have surprisingly found that extended drug release of paclitaxel from a polymer coating on a patterned stent is obtained and consequently, a significant reduction in neointima formation results. The reduction in neointima formation obtained with patterned stents used in accordance with the present invention is surprisingly superior to that obtained using a coiled stent coated with a polymer/paclitaxel matrix.
FIG. 10 shows the release rate of paclitaxel obtained with a stent in accordance with the present invention. In a preferred embodiment, paclitaxel is released from a polymer/paclitaxel coated stent for a time period of at least about 28 days after implantation of stent at the desired location within the body. The patterned stent is coated with an outer coating of polymer/paclitaxel such that the amount of paclitaxel is sufficient to prevent, decrease, eliminate or modify cellular proliferation associated with proliferative disease or disorder. The amount of paclitaxel sufficient to inhibit or prevent proliferative disease will vary according to the size of the patterned stents, but is generally in the range of from about 50 μg to 500 μg per stent. - Procedures for preparing a drug delivery medical device with a polymer coating are presented in the following non-limiting examples.
- A 2 mg/ml solution of paclitaxel is prepared in chloroform. The solution is gently agitated until the paclitaxel is completely dissolved. The solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating and inflated to 2 atm. A total of 100 μl of solution, and hence 200 μg of paclitaxel, is applied to the catheter. The balloon catheter is then dried in air for 30 minutes and in a vacuum oven for 48 hours at 50° C. to evaporate the chloroform. The catheter is then immersed in a solution of 1% dimethyl sulfoxide (DMSO) and phosphate buffered saline (PBS) having a pH of 7.4 for in-vitro drug release. The cumulative amount of paclitaxel released from the catheter coating yields the data shown in
FIGS. 3 a and 3 b. - Solutions containing 1.5 mg/ml and 200 μg/ml of dexamethasone in chloroform, are prepared by gently agitating until the dexamethasone is completely dissolved. The solutions are separately applied via dripping to separate balloon catheters having polyacrylic acid-based coatings and inflated to 2 atm. A total of 100 μl of each solution is applied to each respective catheter, corresponding to dexamethasone loadings of 1.5 mg and 200 μg, respectively. These results can be contrasted with the inability to apply substantial amounts of dexamethasone to polyacrylic acid-based coatings using aqueous solutions, in which case only about 1 μg of dexamethasone can be loaded into such coatings. The balloon catheters are then dried in a vacuum oven for 2 hours at 50° C. to evaporate the chloroform solvent. The catheters are thereafter immersed in PBS (pH=7.4) to track the release of dexamethasone over time. The cumulative amount of dexamethasone released from each catheter yields the data shown in
FIGS. 4 a and 4 b. - Various solutions of molsidomine in volatile solvents are prepared and applied to balloon catheters by the methods indicated in Table I. In the “dip” application technique, each balloon catheter having a polyacrylic acid-based coating is dipped into its respective solution for 10 minutes. In the “pipet” application technique, 200 μl of solution is pipetted onto its respective coated balloon catheter while slowly turning. All samples are dried in an oven for 30 minutes at 50° C. and thereafter immersed in PBS (pH=7.4) to track the release of molsidomine over time. The cumulative amount of molsidomine released from each catheter yields the data shown in
FIGS. 5 a and 5 b. -
TABLE I Molsidomine solution characterization, and methods of applying molsidomine solution to polymer coated catheters. Concentration (mg Molsidomine per Application Sample Solvent ml solvent) technique 1 chloroform 150 dip 2 chloroform 30 pipet 3 chloroform 150 pipet 4 ethanol 30 pipet 5 ethanol 30 dip - Rather than forming a solution of dexamethasone in an organic solvent and then applying this solution to polymer-coated balloon catheters as in Example 2, dexamethasone is added directly to the polymer used to coat the balloon catheters. Dexamethasone is weighed out into 0.05 g, 0.1 g, and 0.2 g samples, each of which is each added to 1 ml lots of polymer topcoat solution containing polyacrylic acid, methyl ethyl ketone, dimethyl formamide, and t-butyl alcohol. The dexamethasone samples are mixed with the polymer topcoat solutions until completely dissolved. The dexamethasone-containing polymer topcoat solutions are separately applied via dripping to separate, uncoated balloon catheters inflated to 2 atm. After drying in a vacuum oven for 2 hours at 50° C., the catheters are immersed in PBS (pH=7.4) to track the release of dexamethasone over time. The cumulative amount of dexamethasone released from each catheter yields the data shown in
FIG. 6 . - Estradiol is provided in both water-soluble and substantially water-insoluble forms. Water-soluble estradiol is applied to a balloon catheter coated with a polyacrylic acid-based coating by i) preparing a 10 mg/ml solution of water-soluble estradiol in deionized, ultra-filtered water; and ii) placing the balloon catheter, inflated to 2 atm, into 200 μl of the solution for 20 minutes. Water-insoluble estradiol is applied to a balloon catheter coated with a polyacrylic-acid based coating by i) preparing a 10 mg/ml solution of substantially water-insoluble estradiol in methanol; and ii) dripping 100 μl of the solution onto the balloon catheter. The catheters are thereafter immersed in PBS (pH=7.4) to track the release of both water-soluble and water-insoluble estradiol over time. Greater release is observed for the substantially water-insoluble form of estradiol when compared to the water-soluble form. The cumulative amount of estradiol released from each catheter yields the data shown in
FIGS. 7 a and 7 b. - A 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared. A total of 50 μl of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating. The paclitaxel from the coated balloon catheter is then released in-vivo to porcine arteries. After release for a predetermined amount of time, the paclitaxel remaining in the coating is extracted using two sequential ethanol washes. The amount of paclitaxel released in the pig bloodstream, as calculated from the amount of paclitaxel loaded into the coating minus that extracted from the coating after delivery, is shown in Table II.
-
TABLE II Amount of paclitaxel released into pig bloodstream from an impregnated, polyacrylic acid-based coated balloon catheter, as a function of delivery time. Amount of pacli- Amount of pacli- % of Amount of taxal extracted taxel released in paclitaxel time in from balloon after bloodstream released in bloodstream delivery (μg) (μg) bloodstream 1 minute 182 ± 1 307 63 5 minutes 160 ± 30 330 68 - A 9.8 mg/ml solution of radio-labeled paclitaxel in chloroform is prepared. A total of 50 μl of the solution is applied via pipet to a balloon catheter having a polyacrylic acid-based coating. The coated balloon catheter is then delivered to an explanted porcine artery for 15 minutes. After delivery, the paclitaxel remaining in the coating is extracted using two sequential ethanol washes. The delivered paclitaxel is extracted from the vessel, also by using two sequential ethanol washes. In addition, the vessel is placed in tissue solvent and counted for paclitaxel. Using these extraction methods, at least 80% of the paclitaxel loaded onto the balloon catheter is recovered, as shown in Table III.
-
TABLE III Paclitaxel recovery from ex vivo delivery to porcine artery. Amount paclitaxel loaded onto balloon 489 μg Amount paclitaxel extracted from the balloon 360 μg after delivery Amount paclitaxel extracted from artery 30 μg Amount paclitaxel counted from tissue solution 1 μg Total paclitaxel measured 391 μg Percentage of paclitaxel recovered 80% - Slotted tube stainless steel stents are coated with polyurethane by spraying a 1 wt % solution of CHRONOFLEX® polyurethane (made by CT Biomaterials) in tetrahydrofuran directly onto the stent surface. The coated stents are dried in a vacuum oven for three hours at 70° C.
- Each polyurethane coated stent is placed in a vial, which is filled to maximum volume (1.5 ml) with a solution of paclitaxel in ethanol, and sealed. The stent is stored in the vial for three days at room temperature. The stent is then removed from the vial and dried for one hour at 65° C.
- The above procedure is conducted using solutions of varying concentrations. Each stent is analyzed for paclitaxel content by extraction in dichloromethane solvent. The results are presented in Table IV below.
Samples samples sample -
TABLE IV Paclitaxel content. Paclitaxel Paclitaxel Coating μg Paclitaxel Sample conc. content Wt. per # (mg/ml) (μg) (μg) μg coating 1 10 44.8 796 0.06 2 10 88.2 859 0.10 3 20 151.2 718 0.21 4 20 127.6 702 0.18 5 30 157.1 736 0.21 6 30 144.3 629 0.23 - These results suggest that paclitaxel loading is relatively independent of paclitaxel concentration above 20 mg/ml, assuming equilibrium is attained in the three-day period. Nevertheless, the 30 mg/ml paclitaxel concentration is chosen for release studies as it produces the maximum paclitaxel loading (21-23%), while still being sufficiently below the saturation concentration for paclitaxel in ethanol (39 mg/ml).
- Seven polyurethane coated stents are loaded using a 30 mg/ml paclitaxel solution, removed and dried as set forth above. Paclitaxel from four of the stents is extracted in dichloromethane solvent. The results of this extraction are presented in Table V below:
-
TABLE V Paclitaxel content. Paclitaxel Paclitaxel Coating μg Paclitaxel Sample conc. content Wt. per # (mg/ml) (μg) (μg) μg coating 1 30 111.7 676 0.17 2 30 50 627 0.08 3 30 45.3 612 0.07 4 30 37.4 602 0.06 - The remaining three stents are immersed in a solution of phosphate buffered saline solution having pH 7.4 at 37° C. Cumulative release as a function of time is presented in
FIG. 8 . - Nylon balloons are coated with polyurethane by dipping into a 9 wt % solution of CHRONOFLEX® polyurethane in dimethylacetamide. The balloons are dried in a vacuum oven overnight at 50° C.
- Each polyurethane coated balloon is loaded with paclitaxel either by dipping the coated balloon into a paclitaxel and ethanol solution or by dripping a known volume of a paclitaxel and ethanol solution onto the balloon surface.
- In the first instance, a stock saturated solution of paclitaxel in ethanol is prepared. Then the polyurethane-coated balloon is inflated and submerged in the paclitaxel stock solution in a tube. The tube and balloon are well-sealed to prevent solvent evaporation. After remaining in the tube overnight, the ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “dip-coated” balloons are prepared in this fashion.
- In the second instance, a stock solution of paclitaxel having a concentration of 10 mg/ml prepared. Twenty ml of this paclitaxel stock solution are then pipetted onto an inflated polyurethane-coated balloon, providing a total mass of 200 mg of paclitaxel per balloon. Afterwards, ethanol is evaporated from the balloon over a suitable time period, such as about fifteen minutes. Five “drip-coated” balloons are prepared in this fashion.
- Two drip-loaded balloons and two dip-loaded balloons are taken and the paclitaxel extracted in dichloromethane to determine total paclitaxel content. The paclitaxel content of the dip-coated balloons is found to be 1093+/−439 mg, while the drip-coated balloons are found to have 215+/−11 μg paclitaxel.
- For comparison, nylon balloons are coated with paclitaxel/polyurethane by dipping the balloons into a dispersion of 14.5 wt % BAHYDROL® polyurethane (made by Bayer) and 2.6 wt % paclitaxel in a mixture of 73.6 vol % N-methylpyrrolidinone and 26.4 vol % water. Balloons are dried in a vacuum oven overnight at 50° C. The dried coatings contain 15% paclitaxel by weight. Nine balloons are formed. Seven balloons are tested for paclitaxel loading yielding an average of 196
- +/−44 μg paclitaxel after extraction in dichloromethane.
- The remaining three drip-loaded balloons from above, the remaining three dip-loaded balloons from above, and the remaining two balloons with the 15% paclitaxel formulated coating are placed in a solution of phosphate buffered saline solution having pH 7.4 at 37° C., and cumulative paclitaxel release is measured as a function of time. The results of this study are presented in
FIG. 9 . - PLA/PCL copolymer obtained from Birmingham Polymers, Inc., Birmingham, Ala., was dissolved in chloroform. Paclitaxel obtained from Hauser, Inc. was then dissolved in the chloroform to form a solution having a 70/30 weight ratio of copolymer/paclitaxel. The solution was then sprayed onto the surface of a 9 mm long balloon-expandable stainless steel NIR® stent obtained from Medinol, Inc., Tel Aviv, Israel. Substantially all exposed surfaces of the stent were covered with the solution. The stent was then dried in a vacuum oven at 50° C. for approximately 2 hr. and a matrix of PLA/PCL copolymer having 200 μg of paclitaxel incorporated therein was thus formed as a coating on the stent. The paclitaxel component of the matrix comprised approximately 30% by weight of the matrix.
- A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a porcine coronary artery. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 50% reduction in the occurrence of neointimal hyperplasia was observed.
- A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 28 days. In comparison to the same stent having no coating, after 28 days, a 70% reduction in the occurrence of neointimal hyperplasia was observed.
- A stent prepared as set forth in Example 10 was inserted via a balloon catheter and expanded into contact with a rabbit iliac. In vitro, the stent delivered 2-3 μg/day of paclitaxel over a period of 56 days. In comparison to the same stent having no coating, after 56 days, a 60% reduction in the occurrence of neointimal hyperplasia was observed.
- The results presented in Table VI below were obtained by Leon et al., “TAXOL®-Coated Coronary Stents: Potential to Reduce Proliferation,” European Society of Cardiology, Vienna, Austria 1998. GR-II® coil stents, available from Cook Inc., Bloomington, Ind., were coated with a biocompatible polymeric coating incorporating 175-200 μg of TAXOL® and exhibiting in vitro release kinetics of 0.75 μg/day for the first 30 days. The stents were placed in porcine coronary arteries and the effect on neointima formation compared to that seen with control stents was analyzed. The results are shown in Table VI below:
-
TABLE VI TAXOL ®-Coated Stents versus Control Control TAXOL ®-coated (N = 10) Stent (N = 9) Reference Vessel 2.9 ± 0.3 3.0 ± 0.2 Diameter (mm) Stent/Artery 1.1 ± 0.1 1.1 ± 0.1 Diameter Stenosis (%) 51 ± 27 27 ± 27* Neointima Area (μm) 669 ± 357 403 ± 197* *p < 0.05 versus control - In contrast to the results obtained in Example 11 above using the NIR® non-coiled stent in a porcine coronary artery (neointimal hyperplasia reduction of 50%), the results obtained with a coil stent and paclitaxel (placed in a porcine coronary artery) show a neointimal hyperplasia reduction of only 40% calculated as follows: [(669-403)/669]×100=40%.
- The results of another study by Leon et al., “TAXOL®-Coated Coronary Stents: Potential to Reduce Proliferation,” European Society of Cardiology, Vienna, Austria 1998 on the effect of coated coil stents on neointima formation using 2 doses of “fast-release” TAXOL® are shown in Table VII below: The results for both “low-dose” and “high-dose” TAXOL®-coated stents are shown in Table VII below:
-
TABLE VII Low-Dose and High Dose TAXOL ®-Coated Stents versus Control Low-Dose High-Dose Control TAXOL ® TAXOL ® (N = 12) (N = 10) (N = 11) Reference 2.8 ± 0.2 2.8 ± 0.7 3.0 ± 0.3 Vessel Diameter (mm) Stent/Artery 1.16 ± 0.09 1.15 ± 0.07 1.14 ± 0.05 Diameter 34.8 ± 15.6 19.3 ± 9.45* 15.1 ± 6.61*† Stenosis (%) Neointima 1.52 ± 0.78 1.07 ± 0.53 0.93 ± 0.5*† Area (μm) *p < 0.05 versus control †p = not significant versus low-dose TAXOL ® - In contrast to the results obtained in Examples 11-13 above using the NIR® non-coiled stent (neointimal hyperplasia reduction of from 50-70%), the above results obtained with a coated coil stent show a neointimal hyperplasia reduction of only 30% and 39%, respectively, calculated as follows: [(1.52-1.07)/1.52]×100=30% (low-dose TAXOL®) and [(1.52-0.93)/1.52)]×100=39% (high-dose TAXOL®).
- A filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10. The filter is sized and constructed to be compressed and passed through the vasculature of a patient to be anchored against an inner wall surface of a blood vessel for capturing blood clots in a blood stream passing therethrough. The filter is described in International Application No. WO 96/17634.
- A filter for placement in the vena cava for capturing blood clots is coated with a PLA/PCL copolymer/paclitaxel matrix in the manner substantially as set forth in Example 10. The filter is also adapted for placement in a blood vessel for capturing blood clots in a blood stream passing therethrough. This filter is provided with struts that minimize the risk of vessel damage if the vessel is compressed asymmetrically. The filter is described in International Application No. WO 96/12448.
- A woven synthetic vascular graft for replacement of a segment a blood vessel is coated with a PLA/PCL copolymer/paclitaxel matrix in a manner substantially as set forth in Example 10. The vascular graft is ravel-resistant due to inclusion of a fusible component and self-supporting due to inclusion of a stiffening component. The vascular graft is described in U.S. Pat. No. 5,509,931.
- It is to be appreciated that the parameters described in the above examples are merely illustrative and that the present invention is not so limited. For example, in each of the examples provided, any suitable polymer may be used for the polymer coating, any suitable drying time periods and temperatures may be used, any suitable organic solvent may be used, any suitable method for applying the polymer coatings to the medical devices may be used, any suitable method for applying the drugs to the polymer coatings may be used, any suitable water-insoluble analogue of the disclosed drugs may be used, and any suitable drug loading concentrations may be used.
- The present invention provides a previously unknown method and medical device for the localized delivery of substantially water-insoluble drugs. The present invention provides, in one embodiment, a paclitaxel/polymer coated stent which has an extended release rate of from about 0.2 to about 7 μg per day, preferably in the range of from about 0.5 to about 5 μg per lay over an extended period of at least about 28 days. In a preferred embodiment of the invention, there is provided a polymer/paclitaxel coated non-coiled stent which has an extended release rate of paclitaxel and which reduces neointima formation in injured blood vessels and other body lumens into which it is placed. The extended release rate is effective to prevent, decrease, eliminate, or modify cellular proliferation associated with neointima formation and/or other proliferative disease or disorder.
- Those with skill in the art may recognize various modifications to the embodiments of the invention described and illustrated herein. Such modifications are meant to be covered by the spirit and scope of the appended claims.
Claims (33)
1. A method of preparing an angioplasty balloon catheter having a balloon with an exterior surface, the method comprising:
mixing at least one drug with a volatile solvent to create a drug solution, the at least one drug comprising paclitaxel and the volatile solvent comprising at least one volatile organic solvent optionally in mixture with water;
applying said drug solution to said exterior surface of the balloon, and
evaporating the volatile solvent.
2. The method of claim 1 , wherein said drug mixture is applied by dipping, or spraying.
3. The method of claim 1 wherein a predetermined amount of said solution of known concentration is applied to the balloon to provide a balloon with a predetermined loading of paclitaxel thereon.
4. The method of claim 3 wherein the solution is applied from a pipette.
5. The method of claim 1 , wherein said volatile solvent comprises ethanol.
6. The method of claim 1 , wherein said volatile solvent is a mixture of a volatile organic solvent and water.
7. The method of claim 1 , wherein said at least one drug consists of paclitaxel.
8. The method of claim 1 , further comprising the step of applying a modulating layer comprising a polymer to said balloon after evaporating said solvent.
9. The method of claim 8 , wherein the modulating layer has a thickness of about 50 to about 5000 Angstroms.
10. The method of claim 9 , wherein the modulating layer has a thickness of about 50-2000 Angstroms.
11. The method of claim 8 , wherein said modulating layer further comprises a drug.
12. The method of claim 13 wherein the modulating layer comprises a silicone.
13. The method of claim 1 wherein said at least one drug comprising paclitaxel further comprises a second drug selected from the group consisting of anticoagulants, anti-inflammatory agents, antimitotics, antithrombogenics, thrombolytics, nitric oxide-containing polymers, vascular cell promoters, growth factors, and mixtures thereof.
14. The method of claim 1 wherein the at least one drug further comprises a member of the group consisting of dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, thymidine kinase inhibitors, lidocaine, bupivacaine, ropivacaine, and mixtures thereof.
15. The method of claim 1 wherein the drug solution is applied to the balloon while the balloon is in a substantially deflated state.
16. The method of claim 1 wherein the drug solution is applied to the balloon while the balloon is in an inflated state.
17. The method of claim 1 wherein total amount of paclitaxel on the balloon after evaporating said volatile solvent is in the range of from about 200 to about 1532 μg.
18. A method of preparing an angioplasty balloon catheter having a balloon with an exterior surface, the method comprising:
mixing at least one drug with a volatile solvent to create a drug solution, the at least one drug selected from the group consisting of paclitaxel dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, mesalamine, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, thymidine kinase inhibitors, lidocaine, bupivacaine, ropivacaine, and mixtures thereof, and the volatile solvent comprising at least one volatile organic solvent optionally in mixture with water;
applying said drug solution to said exterior surface of the balloon, and
evaporating the volatile solvent.
19. A method of delivering paclitaxel, to an inner wall of a blood vessel of a patient from an angioplasty catheter having an expandable balloon with the paclitaxel on an outer surface of the balloon, the method comprising:
providing a balloon of a balloon catheter having a layer consisting of dried paclitaxel on the outer surface of the balloon; and
employing the catheter for vessel dilatation.
20. A method of delivering paclitaxel to an inner wall of a blood vessel the method comprising:
providing a balloon catheter having a balloon an outer surface and a dried layer containing the paclitaxel on the outer surface of the balloon;
advancing the balloon within the blood vessel to a treatment site within the blood vessel;
inflating the balloon at the treatment site to contact the balloon with an inner wall of the blood vessel; and
maintaining the inflated balloon in contact with the inner wall of the blood vessel so as to transfer paclitaxel to the inner wall of the blood vessel.
21. The method of claim 20 , wherein the blood vessel is a coronary artery.
22. The method of claim 20 , wherein at said providing step, the implantable medical device includes a total of from about 152 to about 1532 μg of paclitaxel in said dried layer.
23. The method of claim 20 , wherein the method is performed without implanting a stent within the blood vessel.
24. The method of claim 20 , wherein the balloon comprises a material selected from the group consisting of: a polyamide, polyolefins, polyesters and copolymers thereof.
25. The method of claim 20 , wherein the dried layer consists essentially of about 200 to about 1532 μg of paclitaxel.
26. The method of claim 20 , wherein the time the inflated balloon is in contact with the inner wall of the blood vessel corresponds to said maintaining step.
27. A method of delivering paclitaxel to an inner wall of a blood vessel from a balloon catheter having an expandable balloon with a coating on an outer surface of the balloon, the method comprising:
providing a balloon catheter including a balloon with a dried coating consisting of paclitaxel or a mixture of paclitaxel with another bioactive agent, the dried coating being free of any additional coating atop the dried coating;
advancing the balloon within the blood vessel to a treatment site;
inflating the balloon to directly contact the paclitaxel or mixture of paclitaxel with another bioactive agent with an inner wall of the blood vessel; and
delivering the paclitaxel or mixture of paclitaxel with another bioactive agent to the inner wall of the blood vessel while maintaining the paclitaxel or mixture of paclitaxel with another bioactive agent in direct contact with the inner wall of the blood vessel while the balloon is inflated.
28. The method of claim 27 , where the balloon is attached to a catheter shaft that includes a guide wire lumen and an inflation lumen for inflating the balloon.
29. The method of claim 27 , where the paclitaxel or mixture of paclitaxel with another bioactive agent is brought into direct contact with the vessel wall only while the outer surface of the inflated balloon is maintained in contact with the inner wall of the blood vessel.
30. The method of claim 29 , where the method is performed without implanting a stent within the blood vessel.
31. A method of delivering paclitaxel to an interior wall of a blood vessel from a balloon catheter having an expandable balloon with a paclitaxel coating on an outer surface of the balloon, the method comprising:
providing a balloon catheter without a stent, the balloon catheter having a dried coating consisting of about 200 to about 1532 μg micrograms of a single bioactive coating material consisting of paclitaxel over the outer surface area of the balloon, the balloon catheter being free of any coating atop the paclitaxel, where amounts of the paclitaxel are deliverable to the interior wall upon direct contact of the paclitaxel with the interior wall, and where the balloon has been coated in an inflated state;
advancing the balloon in a deflated state within the blood vessel to a treatment site within the blood vessel; and
inflating the balloon at the treatment site to directly contact the paclitaxel in the coating with the interior wall of the blood vessel and thereby deliver paclitaxel to the interior wall without implanting a stent within the blood vessel.
32. A method of delivering paclitaxel to an inner wall of a blood vessel of a patient from an implantable medical device having an expandable balloon with the paclitaxel on an outer surface of the balloon, the method comprising the steps of:
providing an angioplasty balloon having a dried layer of coating material containing paclitaxel on the outer surface of the balloon, wherein the dried layer of coating material is the outermost layer on the balloon, wherein the balloon has folds, and wherein portions of the dried layer are positioned in the folds;
advancing the balloon within the blood vessel to a treatment site within the blood vessel;
inflating the balloon at the treatment site so as to cause the folds to open so that portions of the balloon come into contact with the inner wall of the blood vessel during which amounts of the coating material containing paclitaxel are transferred to the inner wall of the blood vessel;
maintaining the inflated balloon in contact with the inner wall of the blood vessel; deflating the balloon after said maintaining; and
removing the deflated balloon from the blood vessel.
33. The method of claim 32 , wherein the coating material consists essentially of paclitaxel.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/085,623 US20110196340A1 (en) | 1997-08-13 | 2011-04-13 | Loading and release of water-insoluble drugs |
US13/483,850 US20120239001A1 (en) | 1997-08-13 | 2012-05-30 | Loading and release of water-insoluble drugs |
US13/888,954 US20130304029A1 (en) | 1997-08-13 | 2013-05-07 | Loading and release of water-insoluble drugs |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91013697A | 1997-08-13 | 1997-08-13 | |
US13360398A | 1998-08-13 | 1998-08-13 | |
US09/172,026 US6306166B1 (en) | 1997-08-13 | 1998-10-14 | Loading and release of water-insoluble drugs |
US09/978,763 US20020037358A1 (en) | 1997-08-13 | 2001-10-18 | Loading and release of water-insoluble drugs |
US11/188,850 US20060002973A1 (en) | 1997-08-13 | 2005-07-26 | Loading and release of water-insoluble drugs |
US11/833,717 US20080021385A1 (en) | 1997-08-13 | 2007-08-03 | Loading and release of water-insoluble drugs |
US13/085,623 US20110196340A1 (en) | 1997-08-13 | 2011-04-13 | Loading and release of water-insoluble drugs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/833,717 Division US20080021385A1 (en) | 1997-08-13 | 2007-08-03 | Loading and release of water-insoluble drugs |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/483,850 Continuation US20120239001A1 (en) | 1997-08-13 | 2012-05-30 | Loading and release of water-insoluble drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110196340A1 true US20110196340A1 (en) | 2011-08-11 |
Family
ID=22626067
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/172,026 Expired - Fee Related US6306166B1 (en) | 1997-08-13 | 1998-10-14 | Loading and release of water-insoluble drugs |
US09/978,763 Abandoned US20020037358A1 (en) | 1997-08-13 | 2001-10-18 | Loading and release of water-insoluble drugs |
US11/188,850 Abandoned US20060002973A1 (en) | 1997-08-13 | 2005-07-26 | Loading and release of water-insoluble drugs |
US11/833,717 Abandoned US20080021385A1 (en) | 1997-08-13 | 2007-08-03 | Loading and release of water-insoluble drugs |
US13/085,623 Abandoned US20110196340A1 (en) | 1997-08-13 | 2011-04-13 | Loading and release of water-insoluble drugs |
US13/483,850 Abandoned US20120239001A1 (en) | 1997-08-13 | 2012-05-30 | Loading and release of water-insoluble drugs |
US13/888,954 Abandoned US20130304029A1 (en) | 1997-08-13 | 2013-05-07 | Loading and release of water-insoluble drugs |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/172,026 Expired - Fee Related US6306166B1 (en) | 1997-08-13 | 1998-10-14 | Loading and release of water-insoluble drugs |
US09/978,763 Abandoned US20020037358A1 (en) | 1997-08-13 | 2001-10-18 | Loading and release of water-insoluble drugs |
US11/188,850 Abandoned US20060002973A1 (en) | 1997-08-13 | 2005-07-26 | Loading and release of water-insoluble drugs |
US11/833,717 Abandoned US20080021385A1 (en) | 1997-08-13 | 2007-08-03 | Loading and release of water-insoluble drugs |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/483,850 Abandoned US20120239001A1 (en) | 1997-08-13 | 2012-05-30 | Loading and release of water-insoluble drugs |
US13/888,954 Abandoned US20130304029A1 (en) | 1997-08-13 | 2013-05-07 | Loading and release of water-insoluble drugs |
Country Status (6)
Country | Link |
---|---|
US (7) | US6306166B1 (en) |
EP (2) | EP1800702A3 (en) |
AT (1) | ATE357265T1 (en) |
AU (1) | AU1108800A (en) |
DE (1) | DE69935605T2 (en) |
WO (1) | WO2000021584A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8597720B2 (en) | 2007-01-21 | 2013-12-03 | Hemoteq Ag | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US9011896B2 (en) | 2010-04-19 | 2015-04-21 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US9034362B2 (en) | 2008-09-15 | 2015-05-19 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US9132211B2 (en) | 2008-09-15 | 2015-09-15 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US9586031B2 (en) | 2005-05-11 | 2017-03-07 | Angioscore, Inc. | Methods and systems for delivering substances into luminal walls |
US9592322B2 (en) | 2012-03-27 | 2017-03-14 | Terumo Kabushiki Kaisha | Coating composition and medical device |
US9603974B2 (en) | 2012-03-27 | 2017-03-28 | Terumo Kabushiki Kaisha | Coating composition and medical device |
US9901715B2 (en) | 2012-09-05 | 2018-02-27 | W. L. Gore Associates, Inc. | Retractable sheath devices, systems, and methods |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US10369256B2 (en) | 2009-07-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
US10668188B2 (en) | 2012-10-26 | 2020-06-02 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10806830B2 (en) | 2012-10-26 | 2020-10-20 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10850076B2 (en) | 2012-10-26 | 2020-12-01 | Urotronic, Inc. | Balloon catheters for body lumens |
US10881839B2 (en) | 2012-10-26 | 2021-01-05 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10888640B2 (en) | 2015-04-24 | 2021-01-12 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10898700B2 (en) | 2012-10-26 | 2021-01-26 | Urotronic, Inc. | Balloon catheters for body lumens |
US11504450B2 (en) | 2012-10-26 | 2022-11-22 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11730864B2 (en) | 2015-04-24 | 2023-08-22 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US11938287B2 (en) | 2012-10-26 | 2024-03-26 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11957853B2 (en) | 2023-01-18 | 2024-04-16 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
Families Citing this family (241)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US7896914B2 (en) | 1995-06-07 | 2011-03-01 | Cook Incorporated | Coated implantable medical device |
US7611533B2 (en) | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US7846202B2 (en) | 1995-06-07 | 2010-12-07 | Cook Incorporated | Coated implantable medical device |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7867275B2 (en) | 1995-06-07 | 2011-01-11 | Cook Incorporated | Coated implantable medical device method |
US20060030826A1 (en) * | 1996-06-04 | 2006-02-09 | Vance Products Incorporated,d/b/a Cook Urological Incorporated | Implantable medical device with anti-neoplastic drug |
US20060025726A1 (en) * | 1996-06-04 | 2006-02-02 | Vance Products Incorporated, D/B/A Cook Urological Incorporated | Implantable medical device with pharmacologically active layer |
US20060052757A1 (en) * | 1996-06-04 | 2006-03-09 | Vance Products Incorporated, D/B/A Cook Urological Incorporated | Implantable medical device with analgesic or anesthetic |
US20030093143A1 (en) * | 1999-03-01 | 2003-05-15 | Yiju Zhao | Medical device having surface depressions containing nitric oxide releasing compound |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6433154B1 (en) * | 1997-06-12 | 2002-08-13 | Bristol-Myers Squibb Company | Functional receptor/kinase chimera in yeast cells |
US6306166B1 (en) * | 1997-08-13 | 2001-10-23 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US7445792B2 (en) | 2003-03-10 | 2008-11-04 | Abbott Laboratories | Medical device having a hydration inhibitor |
US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
US8057816B2 (en) * | 1997-09-26 | 2011-11-15 | Abbott Laboratories | Compositions and methods of administering paclitaxel with other drugs using medical devices |
US8257726B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Compositions, systems, kits, and methods of administering rapamycin analogs with paclitaxel using medical devices |
US20070093889A1 (en) * | 1999-01-27 | 2007-04-26 | Wu Benjamin M | Non-Fragmenting Low Friction Bioactive Absorbable Coils for Brain Aneurysm Therapy |
US6241762B1 (en) | 1998-03-30 | 2001-06-05 | Conor Medsystems, Inc. | Expandable medical device with ductile hinges |
US20040254635A1 (en) | 1998-03-30 | 2004-12-16 | Shanley John F. | Expandable medical device for delivery of beneficial agent |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US8029561B1 (en) | 2000-05-12 | 2011-10-04 | Cordis Corporation | Drug combination useful for prevention of restenosis |
US8177743B2 (en) | 1998-05-18 | 2012-05-15 | Boston Scientific Scimed, Inc. | Localized delivery of drug agents |
JP4898991B2 (en) * | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | Sheathed medical device |
US20050171594A1 (en) * | 1998-12-31 | 2005-08-04 | Angiotech International Ag | Stent grafts with bioactive coatings |
US20020065546A1 (en) * | 1998-12-31 | 2002-05-30 | Machan Lindsay S. | Stent grafts with bioactive coatings |
US6709465B2 (en) | 1999-03-18 | 2004-03-23 | Fossa Medical, Inc. | Radially expanding ureteral device |
US6258121B1 (en) * | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
CA2409093C (en) | 2000-05-16 | 2009-07-21 | Regents Of The University Of Minnesota | High mass throughput particle generation using multiple nozzle spraying |
US6974473B2 (en) * | 2000-06-30 | 2005-12-13 | Vascular Architects, Inc. | Function-enhanced thrombolytic AV fistula and method |
DE60135352D1 (en) | 2000-08-30 | 2008-09-25 | Univ Johns Hopkins | DEVICE FOR INTRA-OCCULAR ACTIVE AGGREGATION |
US6620196B1 (en) * | 2000-08-30 | 2003-09-16 | Sdgi Holdings, Inc. | Intervertebral disc nucleus implants and methods |
DE60124285T3 (en) | 2000-09-29 | 2011-03-17 | Cordis Corp., Miami Lakes | COATED MEDICAL EQUIPMENT |
US7261735B2 (en) * | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
AU9463401A (en) | 2000-10-16 | 2002-04-29 | Conor Medsystems Inc | Expandable medical device for delivery of beneficial agent |
US7803149B2 (en) | 2002-07-12 | 2010-09-28 | Cook Incorporated | Coated medical device |
US6607553B1 (en) | 2000-11-17 | 2003-08-19 | B. Braun Medical, Inc. | Method for deploying a thermo-mechanically expandable stent |
EP1339502B1 (en) * | 2000-12-04 | 2004-09-29 | Grüssner, Uwe Emil | Device for Coating an Object with an Active Ingredient and Method for Producing a Partial or Complete Active Ingredient Coating on and in Implants and Onplants as well as Use of or Product Obtained through such a Method |
US20040073294A1 (en) * | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
US20040220660A1 (en) * | 2001-02-05 | 2004-11-04 | Shanley John F. | Bioresorbable stent with beneficial agent reservoirs |
DE10115740A1 (en) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Preparation for restenosis prophylaxis |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
US7247338B2 (en) * | 2001-05-16 | 2007-07-24 | Regents Of The University Of Minnesota | Coating medical devices |
US6656216B1 (en) * | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US7842083B2 (en) | 2001-08-20 | 2010-11-30 | Innovational Holdings, Llc. | Expandable medical device with improved spatial distribution |
WO2003020331A1 (en) * | 2001-09-03 | 2003-03-13 | Oxigene, Inc. | Implants containing combretastatin a-4 |
US8303651B1 (en) | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
GB0121980D0 (en) | 2001-09-11 | 2001-10-31 | Cathnet Science Holding As | Expandable stent |
EP1429819B1 (en) * | 2001-09-24 | 2010-11-24 | Boston Scientific Limited | Optimized dosing for paclitaxel coated stents |
AU2007202976B2 (en) * | 2001-09-24 | 2008-12-04 | Boston Scientific Limited | Optimized dosing for drug coated stents |
US20050025808A1 (en) * | 2001-09-24 | 2005-02-03 | Herrmann Robert A. | Medical devices and methods for inhibiting smooth muscle cell proliferation |
CA2462512C (en) * | 2001-10-01 | 2013-11-05 | Bradley H. Strauss | Use of collagenase to facilitate guide wire crossing in total arterial occlusions |
US20030065382A1 (en) * | 2001-10-02 | 2003-04-03 | Fischell Robert E. | Means and method for the treatment of coronary artery obstructions |
US20030077310A1 (en) | 2001-10-22 | 2003-04-24 | Chandrashekhar Pathak | Stent coatings containing HMG-CoA reductase inhibitors |
US20040111108A1 (en) * | 2001-11-09 | 2004-06-10 | Farnan Robert C. | Balloon catheter with non-deployable stent |
EP1441669B1 (en) | 2001-11-09 | 2009-03-25 | AngioScore, Inc. | Baloon catheter with non-deployable stent |
CA2467239A1 (en) * | 2001-11-14 | 2003-05-22 | Alza Corporation | Catheter injectable depot compositions and uses thereof |
US20070196415A1 (en) * | 2002-11-14 | 2007-08-23 | Guohua Chen | Depot compositions with multiple drug release rate controls and uses thereof |
US7294146B2 (en) | 2001-12-03 | 2007-11-13 | Xtent, Inc. | Apparatus and methods for delivery of variable length stents |
US7137993B2 (en) | 2001-12-03 | 2006-11-21 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US7892273B2 (en) * | 2001-12-03 | 2011-02-22 | Xtent, Inc. | Custom length stent apparatus |
US7147656B2 (en) * | 2001-12-03 | 2006-12-12 | Xtent, Inc. | Apparatus and methods for delivery of braided prostheses |
US20030135266A1 (en) * | 2001-12-03 | 2003-07-17 | Xtent, Inc. | Apparatus and methods for delivery of multiple distributed stents |
US20040186551A1 (en) | 2003-01-17 | 2004-09-23 | Xtent, Inc. | Multiple independent nested stent structures and methods for their preparation and deployment |
US7351255B2 (en) * | 2001-12-03 | 2008-04-01 | Xtent, Inc. | Stent delivery apparatus and method |
US7309350B2 (en) * | 2001-12-03 | 2007-12-18 | Xtent, Inc. | Apparatus and methods for deployment of vascular prostheses |
US7182779B2 (en) * | 2001-12-03 | 2007-02-27 | Xtent, Inc. | Apparatus and methods for positioning prostheses for deployment from a catheter |
US8080048B2 (en) | 2001-12-03 | 2011-12-20 | Xtent, Inc. | Stent delivery for bifurcated vessels |
US7270668B2 (en) * | 2001-12-03 | 2007-09-18 | Xtent, Inc. | Apparatus and methods for delivering coiled prostheses |
WO2003059192A2 (en) * | 2001-12-21 | 2003-07-24 | The Trustees Of Columbia University In The City Of New York | C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis |
US8142412B2 (en) * | 2002-01-03 | 2012-03-27 | Oxira Medical Inc. | Method and apparatus for delivering oxygen and/or other gases to tissue |
US7048962B2 (en) * | 2002-05-02 | 2006-05-23 | Labcoat, Ltd. | Stent coating device |
US6645547B1 (en) * | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US7709048B2 (en) * | 2002-05-02 | 2010-05-04 | Labcoat, Ltd. | Method and apparatus for coating a medical device |
US20030208166A1 (en) * | 2002-05-06 | 2003-11-06 | Schwartz Anthony H. | Implantable device with free-flowing exit and uses thereof |
DE10221055B4 (en) * | 2002-05-10 | 2007-10-25 | Hemoteq Ag | Compounds for hemocompatible coating of surfaces, process for their preparation and their use |
CA2484374C (en) * | 2002-05-09 | 2011-05-17 | Hemoteq Gmbh | Medical products comprising a haemocompatible coating, production and use thereof |
US8313760B2 (en) | 2002-05-24 | 2012-11-20 | Angiotech International Ag | Compositions and methods for coating medical implants |
EP1509256B1 (en) * | 2002-05-24 | 2009-07-22 | Angiotech International Ag | Compositions and methods for coating medical implants |
US7939094B2 (en) | 2002-06-19 | 2011-05-10 | Boston Scientific Scimed, Inc. | Multiphase polymeric drug release region |
US7105175B2 (en) * | 2002-06-19 | 2006-09-12 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
US8211455B2 (en) * | 2002-06-19 | 2012-07-03 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
US7033602B1 (en) | 2002-06-21 | 2006-04-25 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of coating implantable medical devices |
US7056523B1 (en) | 2002-06-21 | 2006-06-06 | Advanced Cardiovascular Systems, Inc. | Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine |
US7794743B2 (en) | 2002-06-21 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Polycationic peptide coatings and methods of making the same |
US7217426B1 (en) | 2002-06-21 | 2007-05-15 | Advanced Cardiovascular Systems, Inc. | Coatings containing polycationic peptides for cardiovascular therapy |
US8506617B1 (en) | 2002-06-21 | 2013-08-13 | Advanced Cardiovascular Systems, Inc. | Micronized peptide coated stent |
US20040001889A1 (en) * | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US7622146B2 (en) * | 2002-07-18 | 2009-11-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices and methods for fabrication thereof |
CA2494400A1 (en) * | 2002-07-31 | 2004-02-05 | Alza Corporation | Injectable multimodal polymer depot compositions and uses thereof |
IL166418A0 (en) * | 2002-07-31 | 2006-01-15 | Alza Corp | Injectable depot compositions and uses thereof |
US20040024448A1 (en) | 2002-08-05 | 2004-02-05 | Chang James W. | Thermoplastic fluoropolymer-coated medical devices |
US7438925B2 (en) * | 2002-08-26 | 2008-10-21 | Biovention Holdings Ltd. | Drug eluting coatings for medical implants |
US7758636B2 (en) | 2002-09-20 | 2010-07-20 | Innovational Holdings Llc | Expandable medical device with openings for delivery of multiple beneficial agents |
DE10244847A1 (en) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medical device for drug delivery |
AU2003300022A1 (en) * | 2002-12-30 | 2004-07-29 | Angiotech International Ag | Silk-containing stent graft |
US8080026B2 (en) | 2003-01-21 | 2011-12-20 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US8313759B2 (en) * | 2003-03-06 | 2012-11-20 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices containing miscible polymer blends for controlled delivery of a therapeutic agent |
AU2004226327A1 (en) | 2003-03-28 | 2004-10-14 | Innovational Holdings, Llc | Implantable medical device with beneficial agent concentration gradient |
AU2004247027A1 (en) * | 2003-05-28 | 2004-12-23 | Innovational Holdings, Llc | Methods of delivering anti-restenotic agents from a stent |
US7241308B2 (en) * | 2003-06-09 | 2007-07-10 | Xtent, Inc. | Stent deployment systems and methods |
US7318945B2 (en) * | 2003-07-09 | 2008-01-15 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent having dipped layers |
US7335185B2 (en) * | 2003-07-18 | 2008-02-26 | Boston Scientific Scimed, Inc. | Protective coatings for medical devices |
US6840569B1 (en) * | 2003-07-22 | 2005-01-11 | Arthur Donald Leigh | Caravan |
US7744645B2 (en) * | 2003-09-29 | 2010-06-29 | Medtronic Vascular, Inc. | Laminated drug-polymer coated stent with dipped and cured layers |
US20050080475A1 (en) * | 2003-10-14 | 2005-04-14 | Xtent, Inc. A Delaware Corporation | Stent delivery devices and methods |
US7553324B2 (en) * | 2003-10-14 | 2009-06-30 | Xtent, Inc. | Fixed stent delivery devices and methods |
US7192440B2 (en) * | 2003-10-15 | 2007-03-20 | Xtent, Inc. | Implantable stent delivery devices and methods |
US7553326B2 (en) * | 2003-11-24 | 2009-06-30 | Sweet Richard M | Method and apparatus for preventing dialysis graft intimal hyperplasia |
US7403966B2 (en) * | 2003-12-08 | 2008-07-22 | Freescale Semiconductor, Inc. | Hardware for performing an arithmetic function |
US20070156225A1 (en) * | 2003-12-23 | 2007-07-05 | Xtent, Inc. | Automated control mechanisms and methods for custom length stent apparatus |
US7326236B2 (en) | 2003-12-23 | 2008-02-05 | Xtent, Inc. | Devices and methods for controlling and indicating the length of an interventional element |
US8309112B2 (en) * | 2003-12-24 | 2012-11-13 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same |
DE102004009318B4 (en) * | 2004-02-26 | 2006-05-04 | Siemens Ag | Device for repeated semi-invasive abrasion of changes on the walls of hollow organs |
US20070027523A1 (en) * | 2004-03-19 | 2007-02-01 | Toner John L | Method of treating vascular disease at a bifurcated vessel using coated balloon |
US8431145B2 (en) | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
ATE534424T1 (en) * | 2004-03-19 | 2011-12-15 | Abbott Lab | MULTIPLE MEDICINAL DELIVERY FROM A BALLOON AND A PROSTHESIS |
US20100030183A1 (en) * | 2004-03-19 | 2010-02-04 | Toner John L | Method of treating vascular disease at a bifurcated vessel using a coated balloon |
US7323006B2 (en) * | 2004-03-30 | 2008-01-29 | Xtent, Inc. | Rapid exchange interventional devices and methods |
US20050226991A1 (en) * | 2004-04-07 | 2005-10-13 | Hossainy Syed F | Methods for modifying balloon of a catheter assembly |
US20050228477A1 (en) * | 2004-04-09 | 2005-10-13 | Xtent, Inc. | Topographic coatings and coating methods for medical devices |
JP2007534389A (en) * | 2004-04-29 | 2007-11-29 | キューブ・メディカル・アクティーゼルスカブ | Balloon used for angiogenesis |
US20050255230A1 (en) * | 2004-05-17 | 2005-11-17 | Clerc Claude O | Method of manufacturing a covered stent |
US7699832B2 (en) * | 2004-05-27 | 2010-04-20 | Medtronic, Inc. | Medical device having a surface including a biologically active agent therein, and methods |
US8317859B2 (en) | 2004-06-28 | 2012-11-27 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
US20050288766A1 (en) * | 2004-06-28 | 2005-12-29 | Xtent, Inc. | Devices and methods for controlling expandable prostheses during deployment |
WO2006017275A1 (en) | 2004-07-13 | 2006-02-16 | The University Of Tennessee Research Foundation | Adhesive composition for carrying therapeutic agents as delivery vehicle on coatings applied to vascular grafts |
WO2006026725A2 (en) | 2004-08-31 | 2006-03-09 | C.R. Bard, Inc. | Self-sealing ptfe graft with kink resistance |
US20060069424A1 (en) * | 2004-09-27 | 2006-03-30 | Xtent, Inc. | Self-constrained segmented stents and methods for their deployment |
US9011831B2 (en) * | 2004-09-30 | 2015-04-21 | Advanced Cardiovascular Systems, Inc. | Methacrylate copolymers for medical devices |
US20060093643A1 (en) * | 2004-11-04 | 2006-05-04 | Stenzel Eric B | Medical device for delivering therapeutic agents over different time periods |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060206139A1 (en) * | 2005-01-19 | 2006-09-14 | Tekulve Kurt J | Vascular occlusion device |
US7402168B2 (en) * | 2005-04-11 | 2008-07-22 | Xtent, Inc. | Custom-length stent delivery system with independently operable expansion elements |
CA2611119A1 (en) * | 2005-06-08 | 2006-12-14 | C.R. Bard Inc. | Grafts and stents having inorganic bio-compatible calcium salt |
CA2610896C (en) | 2005-06-17 | 2014-07-08 | C.R. Bard, Inc. | Vascular graft with kink resistance after clamping |
US9101949B2 (en) | 2005-08-04 | 2015-08-11 | Eilaz Babaev | Ultrasonic atomization and/or seperation system |
US7896539B2 (en) | 2005-08-16 | 2011-03-01 | Bacoustics, Llc | Ultrasound apparatus and methods for mixing liquids and coating stents |
JP5118042B2 (en) * | 2005-09-06 | 2013-01-16 | シー・アール・バード・インコーポレーテッド | Implant for transplantation containing drug crystals |
CN103251449B (en) | 2005-10-13 | 2016-03-02 | 斯恩蒂斯有限公司 | Drug-impregnated encasement |
JP5280852B2 (en) | 2005-11-09 | 2013-09-04 | シー・アール・バード・インコーポレーテッド | Grafts and stent grafts with radiopaque markers |
CN1962155A (en) * | 2005-11-10 | 2007-05-16 | 鸿富锦精密工业(深圳)有限公司 | CO2 laser welding apparatus |
US20080286325A1 (en) * | 2006-01-05 | 2008-11-20 | Med Institute, Inc. | Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent |
US7919108B2 (en) * | 2006-03-10 | 2011-04-05 | Cook Incorporated | Taxane coatings for implantable medical devices |
US8092819B2 (en) * | 2006-01-27 | 2012-01-10 | Cook Medical Technologies LLC. | Implantable medical device coated with a bioactive agent |
US20070179587A1 (en) * | 2006-01-30 | 2007-08-02 | Xtent, Inc. | Apparatus and methods for deployment of custom-length prostheses |
EP1988941A2 (en) * | 2006-01-31 | 2008-11-12 | Nanocopoeia, Inc. | Nanoparticle coating of surfaces |
CA2637883C (en) * | 2006-01-31 | 2015-07-07 | Regents Of The University Of Minnesota | Electrospray coating of objects |
US9108217B2 (en) | 2006-01-31 | 2015-08-18 | Nanocopoeia, Inc. | Nanoparticle coating of surfaces |
US7875284B2 (en) * | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
JP2009530060A (en) | 2006-03-20 | 2009-08-27 | エックステント・インコーポレーテッド | Apparatus and method for deploying connected prosthetic segments |
US20070281117A1 (en) * | 2006-06-02 | 2007-12-06 | Xtent, Inc. | Use of plasma in formation of biodegradable stent coating |
US8703167B2 (en) * | 2006-06-05 | 2014-04-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug |
KR20090045916A (en) * | 2006-07-03 | 2009-05-08 | 헤모텍 아게 | Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open |
US20080051702A1 (en) * | 2006-08-24 | 2008-02-28 | Herrmann Robert A | Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices |
US8394488B2 (en) * | 2006-10-06 | 2013-03-12 | Cordis Corporation | Bioabsorbable device having composite structure for accelerating degradation |
EP2079575B1 (en) | 2006-10-12 | 2021-06-02 | C.R. Bard, Inc. | Methods for making vascular grafts with multiple channels |
US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US9040816B2 (en) * | 2006-12-08 | 2015-05-26 | Nanocopoeia, Inc. | Methods and apparatus for forming photovoltaic cells using electrospray |
US20080152784A1 (en) * | 2006-12-22 | 2008-06-26 | Boston Scientific Scimed, Inc. | Methods of manufacturing coatings and coated medical devices |
DE102007003184A1 (en) * | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Method for loading structured surfaces |
US20080199510A1 (en) * | 2007-02-20 | 2008-08-21 | Xtent, Inc. | Thermo-mechanically controlled implants and methods of use |
US8486132B2 (en) | 2007-03-22 | 2013-07-16 | J.W. Medical Systems Ltd. | Devices and methods for controlling expandable prostheses during deployment |
GR20070100224A (en) * | 2007-04-13 | 2008-11-14 | Κωνστατινος Σπαργιας | Anti-restenosis drug covered and eluting baloon for valvuloplasty of aortic valve stenosis for the prevention of restenosis. |
GR20070100291A (en) * | 2007-05-14 | 2008-12-19 | Κωνστατινος Σπαργιας | Anti-restenosis drug covered and eluting baloons for valvuloplasty of aortic valve stenosiis for the prevention of restenosis. |
US7780095B2 (en) | 2007-07-13 | 2010-08-24 | Bacoustics, Llc | Ultrasound pumping apparatus |
US7753285B2 (en) | 2007-07-13 | 2010-07-13 | Bacoustics, Llc | Echoing ultrasound atomization and/or mixing system |
DE102007036685A1 (en) | 2007-08-03 | 2009-02-05 | Innora Gmbh | Improved drug-coated medical devices their manufacture and use |
DE102007040868A1 (en) * | 2007-08-29 | 2009-04-16 | Innora Gmbh | Balloon catheter with protection against unfolding |
US20090076584A1 (en) * | 2007-09-19 | 2009-03-19 | Xtent, Inc. | Apparatus and methods for deployment of multiple custom-length prostheses |
BRPI0907865A2 (en) * | 2008-02-22 | 2015-07-21 | Angiotech Int Ag | Anti-infectious catheters |
KR101819554B1 (en) | 2008-02-22 | 2018-01-17 | 마이크로 테라퓨틱스 인코포레이티드 | Methods and apparatus for flow restoration |
US9101503B2 (en) * | 2008-03-06 | 2015-08-11 | J.W. Medical Systems Ltd. | Apparatus having variable strut length and methods of use |
WO2009111716A1 (en) * | 2008-03-06 | 2009-09-11 | Boston Scientific Scimed, Inc. | Balloon catheter devices with sheath covering |
JP5601591B2 (en) * | 2008-04-09 | 2014-10-08 | リューベン,アレクサンダー | Method for producing a bioactive surface on a balloon of a balloon catheter and a balloon comprising a bioactive surface made by the method |
WO2009135125A2 (en) * | 2008-05-01 | 2009-11-05 | Bayer Schering Pharma Ag | Catheter balloon drug adherence techniques and methods |
DE102008034826A1 (en) * | 2008-07-22 | 2010-01-28 | Alexander Rübben | A method of creating a bioactive surface on the balloon of a balloon catheter |
US8128951B2 (en) | 2008-09-15 | 2012-03-06 | Cv Ingenuity Corp. | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US8821562B2 (en) | 2008-09-25 | 2014-09-02 | Advanced Bifurcation Systems, Inc. | Partially crimped stent |
US8076529B2 (en) | 2008-09-26 | 2011-12-13 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix for intraluminal drug delivery |
US8226603B2 (en) | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
US8769796B2 (en) | 2008-09-25 | 2014-07-08 | Advanced Bifurcation Systems, Inc. | Selective stent crimping |
US11298252B2 (en) | 2008-09-25 | 2022-04-12 | Advanced Bifurcation Systems Inc. | Stent alignment during treatment of a bifurcation |
CN102215780B (en) | 2008-09-25 | 2015-10-14 | 高级分支系统股份有限公司 | Part crimped stent |
US8049061B2 (en) | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
US8795347B2 (en) | 2008-09-25 | 2014-08-05 | Advanced Bifurcation Systems, Inc. | Methods and systems for treating a bifurcation with provisional side branch stenting |
DE202009004536U1 (en) * | 2009-03-25 | 2010-08-12 | Marx, Karl-Heinz | Set for the creation of an artificial stomach entrance |
US20100285085A1 (en) * | 2009-05-07 | 2010-11-11 | Abbott Cardiovascular Systems Inc. | Balloon coating with drug transfer control via coating thickness |
US8480620B2 (en) * | 2009-12-11 | 2013-07-09 | Abbott Cardiovascular Systems Inc. | Coatings with tunable solubility profile for drug-coated balloon |
US8951595B2 (en) | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
US8900603B2 (en) | 2009-12-18 | 2014-12-02 | Interface Biologics, Inc. | Local delivery of drugs from self assembled coatings |
EP2338534A2 (en) * | 2009-12-21 | 2011-06-29 | Biotronik VI Patent AG | Medical implant, coating method and implantation method |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
WO2011119536A1 (en) | 2010-03-22 | 2011-09-29 | Abbott Cardiovascular Systems Inc. | Stent delivery system having a fibrous matrix covering with improved stent retention |
CA2794080A1 (en) | 2010-03-24 | 2011-09-29 | Advanced Bifurcation Systems, Inc. | System and methods for treating a bifurcation |
WO2011119883A1 (en) | 2010-03-24 | 2011-09-29 | Advanced Bifurcation Systems, Inc. | Stent alignment during treatment of a bifurcation |
EP2383000A1 (en) | 2010-04-19 | 2011-11-02 | InnoRa Gmbh | Limus-coated medical devices |
EP2380605A1 (en) | 2010-04-19 | 2011-10-26 | InnoRa Gmbh | Improved formulations for drug-coated medical devices |
EP2579943B1 (en) | 2010-06-10 | 2019-11-13 | Myriad Medical LLC | Intracavity balloon catheter |
US8632559B2 (en) | 2010-09-21 | 2014-01-21 | Angioscore, Inc. | Method and system for treating valve stenosis |
WO2012039884A1 (en) | 2010-09-23 | 2012-03-29 | Boston Scientific Scimed, Inc. | Drug coated balloon with transferable coating |
JP6034795B2 (en) * | 2010-12-04 | 2016-11-30 | アレクサンダー リュベンAlexander Ruebben | COATING FOR COATING BALLOON OF BALLOON CATHETER AND COATING METHOD |
WO2012084024A1 (en) | 2010-12-21 | 2012-06-28 | Invatec Technology Center Gmbh | Drug eluting balloon for the treatment of stenosis and method for manufacturing the balloon |
EP2672932B1 (en) | 2011-02-08 | 2018-09-19 | Advanced Bifurcation Systems, Inc. | System for treating a bifurcation with a fully crimped stent |
WO2012109382A2 (en) | 2011-02-08 | 2012-08-16 | Advanced Bifurcation Systems, Inc. | Multi-stent and multi-balloon apparatus for treating bifurcations and methods of use |
US20130030406A1 (en) | 2011-07-26 | 2013-01-31 | Medtronic Vascular, Inc. | Textured Dilatation Balloon and Methods |
EP2766062B1 (en) | 2011-10-14 | 2015-08-26 | Innora GmbH | Improved formulations for drug-coated medical devices |
WO2013091722A1 (en) | 2011-12-23 | 2013-06-27 | Innora Gmbh | Drug-coated medical devices |
TWI590843B (en) | 2011-12-28 | 2017-07-11 | 信迪思有限公司 | Films and methods of manufacture |
US9220584B2 (en) | 2012-03-30 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a stent and locally administered adjunctive therapy |
JP6549482B2 (en) | 2012-06-01 | 2019-07-24 | サーモディクス,インコーポレイテッド | Device and method for coating a balloon catheter |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
EP2912121B1 (en) | 2012-10-29 | 2019-09-25 | Ariste Medical, LLC | Polymer coating compositions and coated products |
EP3010560B1 (en) | 2013-06-21 | 2020-01-01 | DePuy Synthes Products, Inc. | Films and methods of manufacture |
US10117668B2 (en) | 2013-10-08 | 2018-11-06 | The Spectranetics Corporation | Balloon catheter with non-deployable stent having improved stability |
US20160303242A1 (en) | 2013-12-09 | 2016-10-20 | Durect Corporation | Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same |
GB2537770B (en) | 2014-04-22 | 2017-09-13 | Ariste Medical Llc | Methods and processes for application of drug delivery polymeric coatings |
JP6008213B2 (en) * | 2014-08-06 | 2016-10-19 | リューベン,アレクサンダー | Method for producing bioactive surface on endoprosthesis or balloon of balloon catheter |
US10695462B2 (en) * | 2014-10-07 | 2020-06-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | On-demand degradable medical devices |
EP3042687B1 (en) | 2015-01-08 | 2020-10-14 | Myriad Medical LLC | Intracavity balloon catheter |
US20170136219A1 (en) * | 2015-11-18 | 2017-05-18 | Angioscore, Inc. | Balloon angioplasty catheter coating to encourage vessel repair and further reduce restenosis |
CN107865982B (en) * | 2016-09-28 | 2020-09-25 | 先健科技(深圳)有限公司 | Drug-coated balloon |
US20200368398A1 (en) * | 2018-01-08 | 2020-11-26 | Foundry Therapeutics, Inc. | Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents |
WO2019222843A1 (en) | 2018-05-22 | 2019-11-28 | Interface Biologics, Inc. | Compositions and methods for delivering drugs to a vessel wall |
US11628466B2 (en) | 2018-11-29 | 2023-04-18 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
EP4340612A1 (en) * | 2021-05-21 | 2024-03-27 | KNOW Bio, LLC | Nitric oxide-releasing devices |
Citations (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US304121A (en) * | 1884-08-26 | Helm munch | ||
US4796629A (en) * | 1987-06-03 | 1989-01-10 | Joseph Grayzel | Stiffened dilation balloon catheter device |
US4906244A (en) * | 1988-10-04 | 1990-03-06 | Cordis Corporation | Balloons for medical devices and fabrication thereof |
US4950239A (en) * | 1988-08-09 | 1990-08-21 | Worldwide Medical Plastics Inc. | Angioplasty balloons and balloon catheters |
US5027996A (en) * | 1989-01-27 | 1991-07-02 | Floquet Monopole | Method of manufacturing a hollow shaft with internal swellings of revolution and shaft obtained by this method |
US5049131A (en) * | 1989-05-31 | 1991-09-17 | Ashridge Ag | Balloon catheter |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5320634A (en) * | 1990-07-03 | 1994-06-14 | Interventional Technologies, Inc. | Balloon catheter with seated cutting edges |
US5328468A (en) * | 1991-10-08 | 1994-07-12 | Terumo Kabushiki Kaisha | Balloon for blood vessel-dilating catheter |
US5344400A (en) * | 1992-04-06 | 1994-09-06 | Terumo Kabushiki Kaisha | Balloon catheters containing molded polyarylenesulfide material |
US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
US5500180A (en) * | 1992-09-30 | 1996-03-19 | C. R. Bard, Inc. | Method of making a distensible dilatation balloon using a block copolymer |
US5556383A (en) * | 1994-03-02 | 1996-09-17 | Scimed Lifesystems, Inc. | Block copolymer elastomer catheter balloons |
US5616149A (en) * | 1990-07-03 | 1997-04-01 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5634901A (en) * | 1992-11-02 | 1997-06-03 | Localmed, Inc. | Method of using a catheter sleeve |
US5797877A (en) * | 1993-10-01 | 1998-08-25 | Boston Scientific Corporation | Medical device balloons containing thermoplastic elastomers |
US5855546A (en) * | 1996-02-29 | 1999-01-05 | Sci-Med Life Systems | Perfusion balloon and radioactive wire delivery system |
US5902299A (en) * | 1997-07-29 | 1999-05-11 | Jayaraman; Swaminathan | Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation |
US5902266A (en) * | 1994-09-12 | 1999-05-11 | Cordis Corporation | Method for delivering a liquid solution to the interior wall surface of a vessel |
US6093463A (en) * | 1997-12-12 | 2000-07-25 | Intella Interventional Systems, Inc. | Medical devices made from improved polymer blends |
US6099454A (en) * | 1996-02-29 | 2000-08-08 | Scimed Life Systems, Inc. | Perfusion balloon and radioactive wire delivery system |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US6240407B1 (en) * | 1998-04-29 | 2001-05-29 | International Business Machines Corp. | Method and apparatus for creating an index in a database system |
US20020010489A1 (en) * | 2000-07-24 | 2002-01-24 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
US6355029B1 (en) * | 1997-12-02 | 2002-03-12 | Cryovascular Systems, Inc. | Apparatus and method for cryogenic inhibition of hyperplasia |
US6391033B2 (en) * | 1996-08-09 | 2002-05-21 | Thomas J. Fogarty | Soluble fixation device and method for stent delivery catheters |
US6418448B1 (en) * | 1999-12-06 | 2002-07-09 | Shyam Sundar Sarkar | Method and apparatus for processing markup language specifications for data and metadata used inside multiple related internet documents to navigate, query and manipulate information from a plurality of object relational databases over the web |
US6432102B2 (en) * | 1999-03-15 | 2002-08-13 | Cryovascular Systems, Inc. | Cryosurgical fluid supply |
US6440990B1 (en) * | 1992-10-09 | 2002-08-27 | Novartis Ag | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US6514245B1 (en) * | 1999-03-15 | 2003-02-04 | Cryovascular Systems, Inc. | Safety cryotherapy catheter |
US20030028210A1 (en) * | 1999-11-04 | 2003-02-06 | Boyle Christopher T. | Balloon catheter having metal balloon and method of making same |
US6527740B1 (en) * | 1999-12-22 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Medical regrooming and drug delivery device |
US6582353B1 (en) * | 1996-02-29 | 2003-06-24 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
US6602246B1 (en) * | 2000-08-18 | 2003-08-05 | Cryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
US20030153870A1 (en) * | 2002-02-14 | 2003-08-14 | Intella Interventional Systems, Inc. | Balloon catheter for creating a longitudinal channel in a lesion and method |
US6685648B2 (en) * | 1996-10-11 | 2004-02-03 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US6730105B2 (en) * | 1988-07-29 | 2004-05-04 | Samuel Shiber | Clover leaf shaped tubular medical device |
US20040117222A1 (en) * | 2002-12-14 | 2004-06-17 | International Business Machines Corporation | System and method for evaluating information aggregates by generation of knowledge capital |
US20040143287A1 (en) * | 2003-01-21 | 2004-07-22 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US20050025848A1 (en) * | 2003-07-30 | 2005-02-03 | Ruey-Fa Huang | Air filter shaping mold |
US20050043678A1 (en) * | 2003-08-20 | 2005-02-24 | Toby Freyman | Medical device with drug delivery member |
US6863861B1 (en) * | 2000-09-28 | 2005-03-08 | Boston Scientific Scimed, Inc. | Process for forming a medical device balloon |
US20050129731A1 (en) * | 2003-11-03 | 2005-06-16 | Roland Horres | Biocompatible, biostable coating of medical surfaces |
US20060002973A1 (en) * | 1997-08-13 | 2006-01-05 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US6995661B2 (en) * | 2003-07-01 | 2006-02-07 | Nissan Motor Co., Ltd. | Vehicular display device |
US20060041225A1 (en) * | 2004-08-17 | 2006-02-23 | Scimed Life Systems, Inc. | Targeted drug delivery device and method |
US20060088596A1 (en) * | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US7037319B2 (en) * | 2002-10-15 | 2006-05-02 | Scimed Life Systems, Inc. | Nanotube paper-based medical device |
US20060121088A1 (en) * | 1996-05-24 | 2006-06-08 | Angiotech International Ag | Compositions and methods for treating or preventing diseases of body passageways |
US7060062B2 (en) * | 2003-06-04 | 2006-06-13 | Cryo Vascular Systems, Inc. | Controllable pressure cryogenic balloon treatment system and method |
US20060129093A1 (en) * | 2004-12-03 | 2006-06-15 | Scimed Life Systems, Inc. | Multiple balloon catheter |
US20060135548A1 (en) * | 2004-12-01 | 2006-06-22 | Vilmos Keri | Processes for producing crystalline macrolides |
US7070576B2 (en) * | 2004-04-30 | 2006-07-04 | Boston Scientific Scimed, Inc. | Directional cutting balloon |
US7081112B2 (en) * | 1999-02-24 | 2006-07-25 | Cryovascular Systems, Inc. | Cryogenically enhanced intravascular interventions |
US20060171982A1 (en) * | 2005-02-03 | 2006-08-03 | Timm Mary J | Deforming surface of drug eluting coating to alter drug release profile of a medical device |
US20060184112A1 (en) * | 2005-02-17 | 2006-08-17 | Horn Daniel J | Medical devices |
US20060193890A1 (en) * | 2002-11-13 | 2006-08-31 | Owens Gary K | Method for loading nanoporous layers with therapeutic agent |
US20070078413A1 (en) * | 2005-08-25 | 2007-04-05 | Stenzel Eric B | Medical device having a lubricant |
US20070106363A1 (en) * | 2005-11-04 | 2007-05-10 | Jan Weber | Medical devices having particle-containing regions with diamond-like coatings |
US20070104766A1 (en) * | 2005-11-10 | 2007-05-10 | Shiping Wang | Elastomeric article with antimicrobial coating |
US7232486B2 (en) * | 2003-03-31 | 2007-06-19 | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság | Crystallization and purification of macrolides |
US20070150466A1 (en) * | 2004-12-29 | 2007-06-28 | Scott Brave | Method and apparatus for suggesting/disambiguation query terms based upon usage patterns observed |
US20070150465A1 (en) * | 2005-12-27 | 2007-06-28 | Scott Brave | Method and apparatus for determining expertise based upon observed usage patterns |
US20070150646A1 (en) * | 2005-12-28 | 2007-06-28 | Chi-Weon Yoon | Semiconductor memory device using pipelined-buffer programming and related method |
US7247338B2 (en) * | 2001-05-16 | 2007-07-24 | Regents Of The University Of Minnesota | Coating medical devices |
US20080031173A1 (en) * | 2005-06-15 | 2008-02-07 | Yan Zhang | Method and apparatus for transmitting traffic indication message in sleep mode |
US20080071358A1 (en) * | 2006-09-18 | 2008-03-20 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20080071350A1 (en) * | 2006-09-18 | 2008-03-20 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20080091008A1 (en) * | 2006-07-25 | 2008-04-17 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
US20080199506A1 (en) * | 2005-05-05 | 2008-08-21 | Roland Horres | Coating of the Entire Surface of Endoprostheses |
US20080208182A1 (en) * | 2004-09-28 | 2008-08-28 | Boston Scientfic Scimed, Inc. | Method for tissue cryotherapy |
US20090088735A1 (en) * | 2004-03-23 | 2009-04-02 | Cryocath Technologies Inc. | Method and apparatus for inflating and deflating balloon catheters |
US20090098176A1 (en) * | 2007-09-10 | 2009-04-16 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
US7527604B2 (en) * | 2005-03-09 | 2009-05-05 | Boston Scientific Scimed, Inc. | Rotatable multi-port therapeutic delivery device |
US20090192537A1 (en) * | 2005-02-11 | 2009-07-30 | Boston Scientific Scimed, Inc. | Cutting Balloon Catheter Having Increased Flexibility Regions |
US20100036585A1 (en) * | 2008-08-06 | 2010-02-11 | Fluid Control Products, Inc. | Programmable fuel pump control |
US20100069838A1 (en) * | 2008-09-12 | 2010-03-18 | Boston Scientific Scimed, Inc. | Devices and systems for delivery of therapeutic agents to body lumens |
US7753876B2 (en) * | 2004-05-10 | 2010-07-13 | Medtronic Vascular, Inc. | Expandable jaw drug delivery catheter |
US7762995B2 (en) * | 2002-04-25 | 2010-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Expandable guide sheath and apparatus and methods using such sheaths |
US20110008260A1 (en) * | 2009-07-10 | 2011-01-13 | Boston Scientific Scimed, Inc. | Use of Nanocrystals for Drug Delivery from a Balloon |
US20110015664A1 (en) * | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucleation of Drug Delivery Balloons to Provide Improved Crystal Size and Density |
US20110020151A1 (en) * | 2009-07-23 | 2011-01-27 | Briggs & Stratton Corporation | Engine blower scroll |
US20110087191A1 (en) * | 2009-10-14 | 2011-04-14 | Boston Scientific Scimed, Inc. | Balloon catheter with shape memory sheath for delivery of therapeutic agent |
US20110152765A1 (en) * | 2009-12-18 | 2011-06-23 | Boston Scientific Scimed, Inc. | Medical device with expandable body for drug delivery by capsules |
US20110160698A1 (en) * | 2007-07-03 | 2011-06-30 | Hemoteq Ag | Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis |
US20110160659A1 (en) * | 2009-12-30 | 2011-06-30 | Boston Scientific Scimed, Inc. | Drug-Delivery Balloons |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
US20110178503A1 (en) * | 2010-01-21 | 2011-07-21 | Boston Scientific Scimed, Inc. | Balloon catheters with therapeutic agent in balloon folds and methods of making the same |
US20120095396A1 (en) * | 2010-10-18 | 2012-04-19 | Boston Scientific Scimed, Inc. | Drug Eluting Medical Device Utilizing Bioadhesives |
Family Cites Families (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US556922A (en) * | 1896-03-24 | gilpatrick | ||
CS173836B1 (en) | 1974-03-19 | 1977-03-31 | ||
US4186745A (en) * | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
US4481323A (en) | 1980-05-07 | 1984-11-06 | Medical Research Associates, Ltd. #2 | Hydrocarbon block copolymer with dispersed polysiloxane |
US4515593A (en) | 1981-12-31 | 1985-05-07 | C. R. Bard, Inc. | Medical tubing having exterior hydrophilic coating for microbiocide absorption therein and method for using same |
CA1191064A (en) | 1981-12-31 | 1985-07-30 | Bard (C. R.), Inc. | Catheter with selectively rigidified portion |
US4769013A (en) | 1982-09-13 | 1988-09-06 | Hydromer, Inc. | Bio-effecting medical material and device |
NZ205680A (en) | 1982-10-01 | 1986-05-09 | Ethicon Inc | Glycolide/epsilon-caprolactone copolymers and sterile surgical articles made therefrom |
US4603152A (en) | 1982-11-05 | 1986-07-29 | Baxter Travenol Laboratories, Inc. | Antimicrobial compositions |
US4644936A (en) * | 1982-11-19 | 1987-02-24 | Iabp | Percutaneous intra-aortic balloon and method for using same |
US4693243A (en) | 1983-01-14 | 1987-09-15 | Buras Sharon Y | Conduit system for directly administering topical anaesthesia to blocked laryngeal-tracheal areas |
US4589873A (en) | 1984-05-29 | 1986-05-20 | Becton, Dickinson And Company | Method of applying a hydrophilic coating to a polymeric substrate and articles prepared thereby |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4784647A (en) | 1986-07-30 | 1988-11-15 | The Kendal Company | Catheter meatal pad device |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
US4886062A (en) * | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US4950256A (en) | 1988-04-07 | 1990-08-21 | Luther Medical Products, Inc. | Non-thrombogenic intravascular time release catheter |
JP2683750B2 (en) | 1988-06-06 | 1997-12-03 | 住友電気工業株式会社 | Catheter balloon |
DE3821544C2 (en) | 1988-06-25 | 1994-04-28 | H Prof Dr Med Just | Dilatation catheter |
US5091205A (en) | 1989-01-17 | 1992-02-25 | Union Carbide Chemicals & Plastics Technology Corporation | Hydrophilic lubricious coatings |
US5087244A (en) | 1989-01-31 | 1992-02-11 | C. R. Bard, Inc. | Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen |
US5041100A (en) | 1989-04-28 | 1991-08-20 | Cordis Corporation | Catheter and hydrophilic, friction-reducing coating thereon |
US4994033A (en) | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US5026607A (en) | 1989-06-23 | 1991-06-25 | C. R. Bard, Inc. | Medical apparatus having protective, lubricious coating |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5135516A (en) | 1989-12-15 | 1992-08-04 | Boston Scientific Corporation | Lubricious antithrombogenic catheters, guidewires and coatings |
DE69110787T2 (en) | 1990-02-28 | 1996-04-04 | Medtronic Inc | INTRALUMINAL PROSTHESIS WITH ACTIVE ELEMENTATION. |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
AU7998091A (en) | 1990-05-17 | 1991-12-10 | Harbor Medical Devices, Inc. | Medical device polymer |
WO1992008510A1 (en) * | 1990-11-09 | 1992-05-29 | Boston Scientific Corporation | Guidewire for crossing occlusions in blood vessels |
US5102402A (en) | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5282823A (en) | 1992-03-19 | 1994-02-01 | Medtronic, Inc. | Intravascular radially expandable stent |
US5599352A (en) | 1992-03-19 | 1997-02-04 | Medtronic, Inc. | Method of making a drug eluting stent |
US5571166A (en) | 1992-03-19 | 1996-11-05 | Medtronic, Inc. | Method of making an intraluminal stent |
US5629008A (en) | 1992-06-02 | 1997-05-13 | C.R. Bard, Inc. | Method and device for long-term delivery of drugs |
US5383928A (en) | 1992-06-10 | 1995-01-24 | Emory University | Stent sheath for local drug delivery |
US5302634A (en) * | 1992-10-15 | 1994-04-12 | Hoppmann Corporation | Cured unsaturated polyester-polyurethane hybrid highly filled resin foams |
US5578075B1 (en) | 1992-11-04 | 2000-02-08 | Daynke Res Inc | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5449382A (en) | 1992-11-04 | 1995-09-12 | Dayton; Michael P. | Minimally invasive bioactivated endoprosthesis for vessel repair |
US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
WO1994021308A1 (en) * | 1993-03-18 | 1994-09-29 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
WO1994027665A1 (en) * | 1993-06-02 | 1994-12-08 | Scimed Life Systems, Inc. | Selective arrangement of lubricous coatings on balloon catheters |
CN100998869A (en) | 1993-07-19 | 2007-07-18 | 血管技术药物公司 | Anti-angiogene compositions and methods of use |
US5994341A (en) * | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
US5380299A (en) | 1993-08-30 | 1995-01-10 | Med Institute, Inc. | Thrombolytic treated intravascular medical device |
DE4421878B4 (en) * | 1994-06-23 | 2007-09-27 | Valeo Wischersysteme Gmbh | Anti-vibration mounting of a windshield wiper drive device |
DE4428851C2 (en) * | 1994-08-04 | 2000-05-04 | Diagnostikforschung Inst | Nanoparticles containing iron, their production and application in diagnostics and therapy |
US5869127A (en) * | 1995-02-22 | 1999-02-09 | Boston Scientific Corporation | Method of providing a substrate with a bio-active/biocompatible coating |
EP0810845A2 (en) | 1995-02-22 | 1997-12-10 | Menlo Care Inc. | Covered expanding mesh stent |
US5605696A (en) | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
ATE314843T1 (en) * | 1996-03-12 | 2006-02-15 | Pg Txl Co Lp | WATER SOLUBLE PACLITAXEL PRODRUGS |
DE19614136A1 (en) * | 1996-04-10 | 1997-10-16 | Inst Neue Mat Gemein Gmbh | Process for the production of agglomerate-free nanoscale iron oxide particles with a hydrolysis-resistant coating |
DE19726282A1 (en) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoscale particles with an iron oxide-containing core surrounded by at least two shells |
AU8782098A (en) | 1997-08-13 | 1999-03-08 | Boston Scientific Limited | Loading and release of water-insoluble drugs |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US6364856B1 (en) * | 1998-04-14 | 2002-04-02 | Boston Scientific Corporation | Medical device with sponge coating for controlled drug release |
JP4898991B2 (en) * | 1998-08-20 | 2012-03-21 | クック メディカル テクノロジーズ エルエルシー | Sheathed medical device |
EP2305324B1 (en) * | 1999-03-25 | 2014-09-17 | Metabolix, Inc. | Medical devices and applications of polyhydroxyalkanoate polymers |
US6186745B1 (en) * | 1999-04-28 | 2001-02-13 | Chemand Corporation | Gas pressurized liquid pump with intermediate chamber |
US7166098B1 (en) * | 1999-12-30 | 2007-01-23 | Advanced Cardiovascular Systems, Inc. | Medical assembly with transducer for local delivery of a therapeutic substance and method of using same |
DE10031740A1 (en) * | 2000-06-29 | 2002-02-14 | Sanguibio Tech Ag | Artificial oxygen carriers from cross-linked modified human or pig hemoglobin with improved properties, processes for their technically simple production from purified material in high yields, and their use |
DE10031742A1 (en) * | 2000-06-29 | 2002-01-17 | Sanguibio Tech Ag | Production of cross-linked hemoglobin useful as artificial oxygen carrier comprises cross-linkage of hemoglobin in presence of a chemically inert effector of the hemoglobin oxygen affinity |
US7803149B2 (en) * | 2002-07-12 | 2010-09-28 | Cook Incorporated | Coated medical device |
US6545097B2 (en) * | 2000-12-12 | 2003-04-08 | Scimed Life Systems, Inc. | Drug delivery compositions and medical devices containing block copolymer |
US7179251B2 (en) * | 2001-01-17 | 2007-02-20 | Boston Scientific Scimed, Inc. | Therapeutic delivery balloon |
US7682387B2 (en) * | 2002-04-24 | 2010-03-23 | Biosensors International Group, Ltd. | Drug-delivery endovascular stent and method for treating restenosis |
US7160317B2 (en) * | 2002-01-04 | 2007-01-09 | Boston Scientific Scimed, Inc. | Multiple-wing balloon catheter to reduce damage to coated expandable medical implants |
US20030171734A1 (en) * | 2002-01-22 | 2003-09-11 | Endobionics, Inc. | Methods and kits for delivering pharmaceutical agents into the coronary vascular adventitia |
US7105175B2 (en) * | 2002-06-19 | 2006-09-12 | Boston Scientific Scimed, Inc. | Implantable or insertable medical devices for controlled delivery of a therapeutic agent |
DE10253634A1 (en) * | 2002-11-13 | 2004-05-27 | Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin | endoprosthesis |
US20070027523A1 (en) * | 2004-03-19 | 2007-02-01 | Toner John L | Method of treating vascular disease at a bifurcated vessel using coated balloon |
US8431145B2 (en) * | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
US20100030183A1 (en) * | 2004-03-19 | 2010-02-04 | Toner John L | Method of treating vascular disease at a bifurcated vessel using a coated balloon |
US20050226991A1 (en) * | 2004-04-07 | 2005-10-13 | Hossainy Syed F | Methods for modifying balloon of a catheter assembly |
US20060013853A1 (en) * | 2004-07-19 | 2006-01-19 | Richard Robert E | Medical devices having conductive substrate and covalently bonded coating layer |
US7771740B2 (en) * | 2004-07-19 | 2010-08-10 | Boston Scientific Scimed, Inc. | Medical devices containing copolymers with graft copolymer endblocks for drug delivery |
US20060025848A1 (en) * | 2004-07-29 | 2006-02-02 | Jan Weber | Medical device having a coating layer with structural elements therein and method of making the same |
US8396548B2 (en) * | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
US7470252B2 (en) * | 2004-09-16 | 2008-12-30 | Boston Scientific Scimed, Inc. | Expandable multi-port therapeutic delivery system |
WO2006036970A2 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Method of thickening a coating using a drug |
US8312836B2 (en) * | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
US7491188B2 (en) * | 2004-10-12 | 2009-02-17 | Boston Scientific Scimed, Inc. | Reinforced and drug-eluting balloon catheters and methods for making same |
US20060085058A1 (en) * | 2004-10-20 | 2006-04-20 | Rosenthal Arthur L | System and method for delivering a biologically active material to a body lumen |
US8722074B2 (en) * | 2005-07-19 | 2014-05-13 | Boston Scientific Scimed, Inc. | Medical devices containing radiation resistant polymers |
US20070067882A1 (en) * | 2005-09-21 | 2007-03-22 | Liliana Atanasoska | Internal medical devices having polyelectrolyte-containing extruded regions |
US8431060B2 (en) * | 2006-01-31 | 2013-04-30 | Abbott Cardiovascular Systems Inc. | Method of fabricating an implantable medical device using gel extrusion and charge induced orientation |
US8287940B2 (en) * | 2006-02-09 | 2012-10-16 | B. Braun Melsungen Ag | Coating method for a folded balloon |
US8518105B2 (en) * | 2006-03-24 | 2013-08-27 | Abbott Cardiovascular System Inc. | Methods and apparatuses for coating a lesion |
KR20090045916A (en) * | 2006-07-03 | 2009-05-08 | 헤모텍 아게 | Manufacture, method and use of drug-eluting medical devices for permanently keeping blood vessels open |
US20080027421A1 (en) * | 2006-07-27 | 2008-01-31 | Vancelette David W | CryoBalloon Treatment for Postpartum Hemorrhage |
US20080057102A1 (en) * | 2006-08-21 | 2008-03-06 | Wouter Roorda | Methods of manufacturing medical devices for controlled drug release |
US20080050415A1 (en) * | 2006-08-25 | 2008-02-28 | Boston Scientic Scimed, Inc. | Polymeric/ceramic composite materials for use in medical devices |
US7897170B2 (en) * | 2006-08-25 | 2011-03-01 | Boston Scientific Scimed, Inc. | Medical devices having improved mechanical performance |
US20080095847A1 (en) * | 2006-10-18 | 2008-04-24 | Thierry Glauser | Stimulus-release carrier, methods of manufacture and methods of treatment |
US8430055B2 (en) * | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
US20080175887A1 (en) * | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
EP2101779A1 (en) * | 2006-12-13 | 2009-09-23 | Angiotech Pharmaceuticals, Inc. | Medical implants with a combination of compounds |
DE102007008479A1 (en) * | 2007-02-21 | 2008-09-04 | Orlowski, Michael, Dr. | Coated Expandable System |
US9370642B2 (en) * | 2007-06-29 | 2016-06-21 | J.W. Medical Systems Ltd. | Adjustable-length drug delivery balloon |
US8690823B2 (en) * | 2007-07-13 | 2014-04-08 | Abbott Cardiovascular Systems Inc. | Drug coated balloon catheter |
US8070798B2 (en) * | 2007-07-20 | 2011-12-06 | Josiah Wilcox | Drug eluting medical device and method |
US8100855B2 (en) * | 2007-09-17 | 2012-01-24 | Abbott Cardiovascular Systems, Inc. | Methods and devices for eluting agents to a vessel |
US20090105687A1 (en) * | 2007-10-05 | 2009-04-23 | Angioscore, Inc. | Scoring catheter with drug delivery membrane |
US7863387B2 (en) * | 2007-10-25 | 2011-01-04 | Boston Scientific Scimed, Inc. | Dehydrofluorination and surface modification of fluoropolymers for drug delivery applications |
US20090112239A1 (en) * | 2007-10-31 | 2009-04-30 | Specialized Vascular Technologies, Inc. | Sticky dilatation balloon and methods of using |
EP3566680A3 (en) * | 2008-06-04 | 2020-02-26 | W.L. Gore & Associates, Inc. | Controlled deployable medical device |
US8187221B2 (en) * | 2008-07-11 | 2012-05-29 | Nexeon Medsystems, Inc. | Nanotube-reinforced balloons for delivering therapeutic agents within or beyond the wall of blood vessels, and methods of making and using same |
JP2011528275A (en) * | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ,インク. | Drug delivery medical device |
US8133199B2 (en) * | 2008-08-27 | 2012-03-13 | Boston Scientific Scimed, Inc. | Electroactive polymer activation system for a medical device |
US20100087783A1 (en) * | 2008-10-07 | 2010-04-08 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents to body lumens |
WO2011028419A1 (en) * | 2009-08-27 | 2011-03-10 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug-coated sheath |
US8617136B2 (en) * | 2009-08-31 | 2013-12-31 | Boston Scientific Scimed, Inc. | Balloon catheter devices with drug delivery extensions |
-
1998
- 1998-10-14 US US09/172,026 patent/US6306166B1/en not_active Expired - Fee Related
-
1999
- 1999-10-14 AU AU11088/00A patent/AU1108800A/en not_active Abandoned
- 1999-10-14 AT AT99954837T patent/ATE357265T1/en not_active IP Right Cessation
- 1999-10-14 EP EP07005256A patent/EP1800702A3/en not_active Withdrawn
- 1999-10-14 WO PCT/US1999/023654 patent/WO2000021584A1/en active IP Right Grant
- 1999-10-14 EP EP99954837A patent/EP1121162B1/en not_active Expired - Lifetime
- 1999-10-14 DE DE69935605T patent/DE69935605T2/en not_active Expired - Lifetime
-
2001
- 2001-10-18 US US09/978,763 patent/US20020037358A1/en not_active Abandoned
-
2005
- 2005-07-26 US US11/188,850 patent/US20060002973A1/en not_active Abandoned
-
2007
- 2007-08-03 US US11/833,717 patent/US20080021385A1/en not_active Abandoned
-
2011
- 2011-04-13 US US13/085,623 patent/US20110196340A1/en not_active Abandoned
-
2012
- 2012-05-30 US US13/483,850 patent/US20120239001A1/en not_active Abandoned
-
2013
- 2013-05-07 US US13/888,954 patent/US20130304029A1/en not_active Abandoned
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US304121A (en) * | 1884-08-26 | Helm munch | ||
US4796629A (en) * | 1987-06-03 | 1989-01-10 | Joseph Grayzel | Stiffened dilation balloon catheter device |
US6730105B2 (en) * | 1988-07-29 | 2004-05-04 | Samuel Shiber | Clover leaf shaped tubular medical device |
US4950239A (en) * | 1988-08-09 | 1990-08-21 | Worldwide Medical Plastics Inc. | Angioplasty balloons and balloon catheters |
US4906244A (en) * | 1988-10-04 | 1990-03-06 | Cordis Corporation | Balloons for medical devices and fabrication thereof |
US5027996A (en) * | 1989-01-27 | 1991-07-02 | Floquet Monopole | Method of manufacturing a hollow shaft with internal swellings of revolution and shaft obtained by this method |
US5049131A (en) * | 1989-05-31 | 1991-09-17 | Ashridge Ag | Balloon catheter |
US5320634A (en) * | 1990-07-03 | 1994-06-14 | Interventional Technologies, Inc. | Balloon catheter with seated cutting edges |
US5616149A (en) * | 1990-07-03 | 1997-04-01 | Cedars-Sinai Medical Center | Balloon catheter with cutting edge |
US5180366A (en) * | 1990-10-10 | 1993-01-19 | Woods W T | Apparatus and method for angioplasty and for preventing re-stenosis |
US5328468A (en) * | 1991-10-08 | 1994-07-12 | Terumo Kabushiki Kaisha | Balloon for blood vessel-dilating catheter |
US5344400A (en) * | 1992-04-06 | 1994-09-06 | Terumo Kabushiki Kaisha | Balloon catheters containing molded polyarylenesulfide material |
US5500180A (en) * | 1992-09-30 | 1996-03-19 | C. R. Bard, Inc. | Method of making a distensible dilatation balloon using a block copolymer |
US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
US6440990B1 (en) * | 1992-10-09 | 2002-08-27 | Novartis Ag | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
US5876374A (en) * | 1992-11-02 | 1999-03-02 | Localmed, Inc. | Catheter sleeve for use with a balloon catheter |
US5634901A (en) * | 1992-11-02 | 1997-06-03 | Localmed, Inc. | Method of using a catheter sleeve |
US5797877A (en) * | 1993-10-01 | 1998-08-25 | Boston Scientific Corporation | Medical device balloons containing thermoplastic elastomers |
US5556383A (en) * | 1994-03-02 | 1996-09-17 | Scimed Lifesystems, Inc. | Block copolymer elastomer catheter balloons |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5902266A (en) * | 1994-09-12 | 1999-05-11 | Cordis Corporation | Method for delivering a liquid solution to the interior wall surface of a vessel |
US6099454A (en) * | 1996-02-29 | 2000-08-08 | Scimed Life Systems, Inc. | Perfusion balloon and radioactive wire delivery system |
US6582353B1 (en) * | 1996-02-29 | 2003-06-24 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
US5855546A (en) * | 1996-02-29 | 1999-01-05 | Sci-Med Life Systems | Perfusion balloon and radioactive wire delivery system |
US6398708B1 (en) * | 1996-02-29 | 2002-06-04 | Scimed Life Systems, Inc. | Perfusion balloon and radioactive wire delivery system |
US20060121088A1 (en) * | 1996-05-24 | 2006-06-08 | Angiotech International Ag | Compositions and methods for treating or preventing diseases of body passageways |
US6391033B2 (en) * | 1996-08-09 | 2002-05-21 | Thomas J. Fogarty | Soluble fixation device and method for stent delivery catheters |
US6685648B2 (en) * | 1996-10-11 | 2004-02-03 | Transvascular, Inc. | Systems and methods for delivering drugs to selected locations within the body |
US6511477B2 (en) * | 1997-03-13 | 2003-01-28 | Biocardia, Inc. | Method of drug delivery to interstitial regions of the myocardium |
US5902299A (en) * | 1997-07-29 | 1999-05-11 | Jayaraman; Swaminathan | Cryotherapy method for reducing tissue injury after balloon angioplasty or stent implantation |
US20060002973A1 (en) * | 1997-08-13 | 2006-01-05 | Scimed Life Systems, Inc. | Loading and release of water-insoluble drugs |
US6355029B1 (en) * | 1997-12-02 | 2002-03-12 | Cryovascular Systems, Inc. | Apparatus and method for cryogenic inhibition of hyperplasia |
US6908462B2 (en) * | 1997-12-02 | 2005-06-21 | Cryovascular Systems, Inc. | Apparatus and method for cryogenic inhibition of hyperplasia |
US6093463A (en) * | 1997-12-12 | 2000-07-25 | Intella Interventional Systems, Inc. | Medical devices made from improved polymer blends |
US6240407B1 (en) * | 1998-04-29 | 2001-05-29 | International Business Machines Corp. | Method and apparatus for creating an index in a database system |
US7081112B2 (en) * | 1999-02-24 | 2006-07-25 | Cryovascular Systems, Inc. | Cryogenically enhanced intravascular interventions |
US6432102B2 (en) * | 1999-03-15 | 2002-08-13 | Cryovascular Systems, Inc. | Cryosurgical fluid supply |
US6514245B1 (en) * | 1999-03-15 | 2003-02-04 | Cryovascular Systems, Inc. | Safety cryotherapy catheter |
US6203551B1 (en) * | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
US20030028210A1 (en) * | 1999-11-04 | 2003-02-06 | Boyle Christopher T. | Balloon catheter having metal balloon and method of making same |
US6418448B1 (en) * | 1999-12-06 | 2002-07-09 | Shyam Sundar Sarkar | Method and apparatus for processing markup language specifications for data and metadata used inside multiple related internet documents to navigate, query and manipulate information from a plurality of object relational databases over the web |
US6527740B1 (en) * | 1999-12-22 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Medical regrooming and drug delivery device |
US20020010489A1 (en) * | 2000-07-24 | 2002-01-24 | Jeffrey Grayzel | Stiffened balloon catheter for dilatation and stenting |
US6602246B1 (en) * | 2000-08-18 | 2003-08-05 | Cryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
US6863861B1 (en) * | 2000-09-28 | 2005-03-08 | Boston Scientific Scimed, Inc. | Process for forming a medical device balloon |
US7247338B2 (en) * | 2001-05-16 | 2007-07-24 | Regents Of The University Of Minnesota | Coating medical devices |
US20030153870A1 (en) * | 2002-02-14 | 2003-08-14 | Intella Interventional Systems, Inc. | Balloon catheter for creating a longitudinal channel in a lesion and method |
US7762995B2 (en) * | 2002-04-25 | 2010-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Expandable guide sheath and apparatus and methods using such sheaths |
US7037319B2 (en) * | 2002-10-15 | 2006-05-02 | Scimed Life Systems, Inc. | Nanotube paper-based medical device |
US20060193890A1 (en) * | 2002-11-13 | 2006-08-31 | Owens Gary K | Method for loading nanoporous layers with therapeutic agent |
US20040117222A1 (en) * | 2002-12-14 | 2004-06-17 | International Business Machines Corporation | System and method for evaluating information aggregates by generation of knowledge capital |
US20040143287A1 (en) * | 2003-01-21 | 2004-07-22 | Angioscore, Inc. | Apparatus and methods for treating hardened vascular lesions |
US7232486B2 (en) * | 2003-03-31 | 2007-06-19 | TEVA Gyógyszergyár Zártkörűen Működő Részvénytársaság | Crystallization and purification of macrolides |
US7060062B2 (en) * | 2003-06-04 | 2006-06-13 | Cryo Vascular Systems, Inc. | Controllable pressure cryogenic balloon treatment system and method |
US6995661B2 (en) * | 2003-07-01 | 2006-02-07 | Nissan Motor Co., Ltd. | Vehicular display device |
US20050025848A1 (en) * | 2003-07-30 | 2005-02-03 | Ruey-Fa Huang | Air filter shaping mold |
US20050043678A1 (en) * | 2003-08-20 | 2005-02-24 | Toby Freyman | Medical device with drug delivery member |
US20050129731A1 (en) * | 2003-11-03 | 2005-06-16 | Roland Horres | Biocompatible, biostable coating of medical surfaces |
US20090088735A1 (en) * | 2004-03-23 | 2009-04-02 | Cryocath Technologies Inc. | Method and apparatus for inflating and deflating balloon catheters |
US7070576B2 (en) * | 2004-04-30 | 2006-07-04 | Boston Scientific Scimed, Inc. | Directional cutting balloon |
US7753876B2 (en) * | 2004-05-10 | 2010-07-13 | Medtronic Vascular, Inc. | Expandable jaw drug delivery catheter |
US20060041225A1 (en) * | 2004-08-17 | 2006-02-23 | Scimed Life Systems, Inc. | Targeted drug delivery device and method |
US20060088596A1 (en) * | 2004-09-28 | 2006-04-27 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
US20080208182A1 (en) * | 2004-09-28 | 2008-08-28 | Boston Scientfic Scimed, Inc. | Method for tissue cryotherapy |
US20060135548A1 (en) * | 2004-12-01 | 2006-06-22 | Vilmos Keri | Processes for producing crystalline macrolides |
US20060129093A1 (en) * | 2004-12-03 | 2006-06-15 | Scimed Life Systems, Inc. | Multiple balloon catheter |
US20080040314A1 (en) * | 2004-12-29 | 2008-02-14 | Scott Brave | Method and Apparatus for Identifying, Extracting, Capturing, and Leveraging Expertise and Knowledge |
US20070150466A1 (en) * | 2004-12-29 | 2007-06-28 | Scott Brave | Method and apparatus for suggesting/disambiguation query terms based upon usage patterns observed |
US20080104004A1 (en) * | 2004-12-29 | 2008-05-01 | Scott Brave | Method and Apparatus for Identifying, Extracting, Capturing, and Leveraging Expertise and Knowledge |
US20060171982A1 (en) * | 2005-02-03 | 2006-08-03 | Timm Mary J | Deforming surface of drug eluting coating to alter drug release profile of a medical device |
US20090192537A1 (en) * | 2005-02-11 | 2009-07-30 | Boston Scientific Scimed, Inc. | Cutting Balloon Catheter Having Increased Flexibility Regions |
US20060184112A1 (en) * | 2005-02-17 | 2006-08-17 | Horn Daniel J | Medical devices |
US7527604B2 (en) * | 2005-03-09 | 2009-05-05 | Boston Scientific Scimed, Inc. | Rotatable multi-port therapeutic delivery device |
US20080199506A1 (en) * | 2005-05-05 | 2008-08-21 | Roland Horres | Coating of the Entire Surface of Endoprostheses |
US20080031173A1 (en) * | 2005-06-15 | 2008-02-07 | Yan Zhang | Method and apparatus for transmitting traffic indication message in sleep mode |
US20070078413A1 (en) * | 2005-08-25 | 2007-04-05 | Stenzel Eric B | Medical device having a lubricant |
US20070106363A1 (en) * | 2005-11-04 | 2007-05-10 | Jan Weber | Medical devices having particle-containing regions with diamond-like coatings |
US20070104766A1 (en) * | 2005-11-10 | 2007-05-10 | Shiping Wang | Elastomeric article with antimicrobial coating |
US20070150465A1 (en) * | 2005-12-27 | 2007-06-28 | Scott Brave | Method and apparatus for determining expertise based upon observed usage patterns |
US20070150470A1 (en) * | 2005-12-27 | 2007-06-28 | Scott Brave | Method and apparatus for determining peer groups based upon observed usage patterns |
US20070150515A1 (en) * | 2005-12-27 | 2007-06-28 | Scott Brave | Method and apparatus for determining usefulness of a digital asset |
US20070150646A1 (en) * | 2005-12-28 | 2007-06-28 | Chi-Weon Yoon | Semiconductor memory device using pipelined-buffer programming and related method |
US20080091008A1 (en) * | 2006-07-25 | 2008-04-17 | Abbott Laboratories | Methods of manufacturing crystalline forms of rapamycin analogs |
US20080071350A1 (en) * | 2006-09-18 | 2008-03-20 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20080071358A1 (en) * | 2006-09-18 | 2008-03-20 | Boston Scientific Scimed, Inc. | Endoprostheses |
US20110160698A1 (en) * | 2007-07-03 | 2011-06-30 | Hemoteq Ag | Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis |
US20090098176A1 (en) * | 2007-09-10 | 2009-04-16 | Boston Scientific Scimed, Inc. | Medical devices with triggerable bioadhesive material |
US20100036585A1 (en) * | 2008-08-06 | 2010-02-11 | Fluid Control Products, Inc. | Programmable fuel pump control |
US20100069838A1 (en) * | 2008-09-12 | 2010-03-18 | Boston Scientific Scimed, Inc. | Devices and systems for delivery of therapeutic agents to body lumens |
US20110008260A1 (en) * | 2009-07-10 | 2011-01-13 | Boston Scientific Scimed, Inc. | Use of Nanocrystals for Drug Delivery from a Balloon |
US20110015664A1 (en) * | 2009-07-17 | 2011-01-20 | Boston Scientific Scimed, Inc. | Nucleation of Drug Delivery Balloons to Provide Improved Crystal Size and Density |
US20110020151A1 (en) * | 2009-07-23 | 2011-01-27 | Briggs & Stratton Corporation | Engine blower scroll |
US20110087191A1 (en) * | 2009-10-14 | 2011-04-14 | Boston Scientific Scimed, Inc. | Balloon catheter with shape memory sheath for delivery of therapeutic agent |
US20110152765A1 (en) * | 2009-12-18 | 2011-06-23 | Boston Scientific Scimed, Inc. | Medical device with expandable body for drug delivery by capsules |
US20110160659A1 (en) * | 2009-12-30 | 2011-06-30 | Boston Scientific Scimed, Inc. | Drug-Delivery Balloons |
US20110160645A1 (en) * | 2009-12-31 | 2011-06-30 | Boston Scientific Scimed, Inc. | Cryo Activated Drug Delivery and Cutting Balloons |
US20110178503A1 (en) * | 2010-01-21 | 2011-07-21 | Boston Scientific Scimed, Inc. | Balloon catheters with therapeutic agent in balloon folds and methods of making the same |
US20120095396A1 (en) * | 2010-10-18 | 2012-04-19 | Boston Scientific Scimed, Inc. | Drug Eluting Medical Device Utilizing Bioadhesives |
Non-Patent Citations (1)
Title |
---|
Axel, D.I., et. al., "Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug Delivery" 1997, Circulation, 96, pp. 636-645 * |
Cited By (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10076641B2 (en) | 2005-05-11 | 2018-09-18 | The Spectranetics Corporation | Methods and systems for delivering substances into luminal walls |
US11420030B2 (en) | 2005-05-11 | 2022-08-23 | Angioscore, Inc. | Methods and systems for delivering substances into luminal walls |
US9586031B2 (en) | 2005-05-11 | 2017-03-07 | Angioscore, Inc. | Methods and systems for delivering substances into luminal walls |
US10342960B2 (en) | 2005-05-11 | 2019-07-09 | Angioscore, Inc. | Methods and systems for delivering substances into luminal walls |
US8597720B2 (en) | 2007-01-21 | 2013-12-03 | Hemoteq Ag | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
US9192697B2 (en) | 2007-07-03 | 2015-11-24 | Hemoteq Ag | Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis |
US9132211B2 (en) | 2008-09-15 | 2015-09-15 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10117970B2 (en) | 2008-09-15 | 2018-11-06 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9603973B2 (en) | 2008-09-15 | 2017-03-28 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10046093B2 (en) | 2008-09-15 | 2018-08-14 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9034362B2 (en) | 2008-09-15 | 2015-05-19 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US9198968B2 (en) | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10987452B2 (en) | 2008-09-15 | 2021-04-27 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10314948B2 (en) | 2008-09-15 | 2019-06-11 | The Spectranetics Coporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
US10369256B2 (en) | 2009-07-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
US11278648B2 (en) | 2009-07-10 | 2022-03-22 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
US10080821B2 (en) | 2009-07-17 | 2018-09-25 | Boston Scientific Scimed, Inc. | Nucleation of drug delivery balloons to provide improved crystal size and density |
US9101684B2 (en) | 2010-04-19 | 2015-08-11 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US10383982B2 (en) | 2010-04-19 | 2019-08-20 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US9072812B2 (en) | 2010-04-19 | 2015-07-07 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US9011896B2 (en) | 2010-04-19 | 2015-04-21 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US9173977B2 (en) | 2010-04-19 | 2015-11-03 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US10046092B2 (en) | 2010-04-19 | 2018-08-14 | The Spectranetics Corporation | Coating formulations for scoring or cutting balloon catheters |
US10583225B2 (en) | 2010-04-19 | 2020-03-10 | Angioscore, Inc. | Method of coating scoring or cutting balloon catheters |
US9770536B2 (en) | 2010-04-19 | 2017-09-26 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US10314947B2 (en) | 2010-04-19 | 2019-06-11 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US9078951B2 (en) | 2010-04-19 | 2015-07-14 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US10471184B2 (en) | 2010-04-19 | 2019-11-12 | Angioscore, Inc. | Coating formulations for scoring or cutting balloon catheters |
US8889211B2 (en) | 2010-09-02 | 2014-11-18 | Boston Scientific Scimed, Inc. | Coating process for drug delivery balloons using heat-induced rewrap memory |
US9415193B2 (en) | 2011-03-04 | 2016-08-16 | W. L. Gore & Associates, Inc. | Eluting medical devices |
US8669360B2 (en) | 2011-08-05 | 2014-03-11 | Boston Scientific Scimed, Inc. | Methods of converting amorphous drug substance into crystalline form |
US9056152B2 (en) | 2011-08-25 | 2015-06-16 | Boston Scientific Scimed, Inc. | Medical device with crystalline drug coating |
US9592322B2 (en) | 2012-03-27 | 2017-03-14 | Terumo Kabushiki Kaisha | Coating composition and medical device |
US9603974B2 (en) | 2012-03-27 | 2017-03-28 | Terumo Kabushiki Kaisha | Coating composition and medical device |
US10045960B2 (en) | 2012-03-27 | 2018-08-14 | Terumo Kabushiki Kaisha | Coating composition and medical device |
US9956385B2 (en) | 2012-06-28 | 2018-05-01 | The Spectranetics Corporation | Post-processing of a medical device to control morphology and mechanical properties |
US10173038B2 (en) | 2012-09-05 | 2019-01-08 | W. L. Gore & Associates, Inc. | Retractable sheath devices, systems, and methods |
US9901715B2 (en) | 2012-09-05 | 2018-02-27 | W. L. Gore Associates, Inc. | Retractable sheath devices, systems, and methods |
US10881839B2 (en) | 2012-10-26 | 2021-01-05 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11471656B2 (en) | 2012-10-26 | 2022-10-18 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10806830B2 (en) | 2012-10-26 | 2020-10-20 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11938287B2 (en) | 2012-10-26 | 2024-03-26 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10898700B2 (en) | 2012-10-26 | 2021-01-26 | Urotronic, Inc. | Balloon catheters for body lumens |
US10675386B2 (en) | 2012-10-26 | 2020-06-09 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10987451B2 (en) | 2012-10-26 | 2021-04-27 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10994104B2 (en) | 2012-10-26 | 2021-05-04 | Urotronic, Inc. | Balloon catheters for body lumens |
US10994103B2 (en) | 2012-10-26 | 2021-05-04 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10668188B2 (en) | 2012-10-26 | 2020-06-02 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US11925729B2 (en) | 2012-10-26 | 2024-03-12 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11439801B2 (en) | 2012-10-26 | 2022-09-13 | Urotronic, Inc. | Balloon catheters for body lumens |
US11471655B2 (en) | 2012-10-26 | 2022-10-18 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US10850076B2 (en) | 2012-10-26 | 2020-12-01 | Urotronic, Inc. | Balloon catheters for body lumens |
US11826533B2 (en) | 2012-10-26 | 2023-11-28 | Urotronic, Inc. | Balloon catheters for body lumens |
US11504450B2 (en) | 2012-10-26 | 2022-11-22 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11648338B2 (en) | 2012-10-26 | 2023-05-16 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11648337B2 (en) | 2012-10-26 | 2023-05-16 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
US11826532B2 (en) | 2012-10-26 | 2023-11-28 | Urotronic, Inc. | Balloon catheters for body lumens |
US10525171B2 (en) | 2014-01-24 | 2020-01-07 | The Spectranetics Corporation | Coatings for medical devices |
US11730864B2 (en) | 2015-04-24 | 2023-08-22 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US11484628B2 (en) | 2015-04-24 | 2022-11-01 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US11904072B2 (en) | 2015-04-24 | 2024-02-20 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US10888640B2 (en) | 2015-04-24 | 2021-01-12 | Urotronic, Inc. | Drug coated balloon catheters for nonvascular strictures |
US11957853B2 (en) | 2023-01-18 | 2024-04-16 | Urotronic, Inc. | Drug-coated balloon catheters for body lumens |
Also Published As
Publication number | Publication date |
---|---|
DE69935605D1 (en) | 2007-05-03 |
EP1800702A3 (en) | 2008-03-05 |
US20120239001A1 (en) | 2012-09-20 |
AU1108800A (en) | 2000-05-01 |
ATE357265T1 (en) | 2007-04-15 |
EP1121162B1 (en) | 2007-03-21 |
US20060002973A1 (en) | 2006-01-05 |
WO2000021584A1 (en) | 2000-04-20 |
EP1121162A1 (en) | 2001-08-08 |
US6306166B1 (en) | 2001-10-23 |
EP1800702A2 (en) | 2007-06-27 |
US20130304029A1 (en) | 2013-11-14 |
US20020037358A1 (en) | 2002-03-28 |
DE69935605T2 (en) | 2007-11-29 |
US20080021385A1 (en) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6306166B1 (en) | Loading and release of water-insoluble drugs | |
US6589546B2 (en) | Polymeric coatings for controlled delivery of active agents | |
JP4493655B2 (en) | Method for applying a drug polymer coating to a stent | |
US8227016B2 (en) | Laminated drug-polymer coated stent with dipped and cured layers | |
EP1011743B1 (en) | Loading and release of water-insoluble drugs | |
US8001925B2 (en) | Drug-polymer coated stent | |
US20050180919A1 (en) | Stent with radiopaque and encapsulant coatings | |
US20050159809A1 (en) | Implantable medical devices for treating or preventing restenosis | |
US20060015170A1 (en) | Contrast coated stent and method of fabrication | |
EP3603688A1 (en) | Limus coatings and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION |